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QWBA quantitative whole-body autoradiography 
RMT receptor-mediated transport 
RO receptor occupancy 
S-D Sprague-Dawley 
t½ terminal elimination half-life 
TEM transmission electron microscopy 
Tf transferrin  
TfR transferrin receptor 
TPMT thiopurine methyltransferase 
TJ tight junction 
ULOQ upper limit of quantification 
Vdss steady-state volume of distribution 
WBSFI whole-body section fluorescence imaging 
XO xanthine oxidase 
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ABSTRACT 
 
The endothelial cells of brain capillaries form the so-called blood brain barrier (BBB) and 
the BBB protects the central nervous system (CNS) from the entry of neurotoxins and blood 
components. Consequently, more than 98% of all potential CNS drugs fail because they cannot 
cross the BBB, to gain access to disease targets. Despite significant research efforts in this area, 
the delivery of drugs across the BBB into the brain remains the Achilles heel in CNS drug 
development. Therefore in this thesis, we describe the development and testing of ultra-small 
gold nanoparticles that can traffic drug molecules across the BBB into brain parenchyma, with 
the potential of also increasing the receptor-binding affinity of drugs. We present compelling 
results of in vitro and in vivo studies, combined with imaging and bioanalytical techniques to 
demonstrate the superior pharmacokinetics, brain penetration, and receptor binding of drugs 
conjugated to gold nanoparticles (AuNPs). 
In chapter one, we provide an introduction to the global impact of CNS diseases and 
discuss the physiological basis of the CNS. The role of the highly specialized BBB in 
transporting molecules such as nutrients into the brain, while restricting the uptake of drug 
candidates, is discussed. Various CNS drug delivery and targeting strategies are described as 
well as their advantages and limitations. Finally we describe unique features of gold 
nanoparticles (AuNPs) that make them attractive as drug carriers for CNS delivery.   
Chapter two describes a novel CNS drug-delivery strategy involving the conjugation of 
the anticancer agent 6-mercaptopurine riboside to AuNPs (6-MPR-AuNPs). 6-MPR and its 
antimetabolites have short half-life due to rapid metabolism by liver xanthine oxidase. The  
6-MPR-AuNPs drastically decreased the clearance of 6-MPR from 6190 ± 810 to 22.45 ± 1.95 
mL/min/kg. Correspondingly, the half-life of 6-MPR increased from 13.8 ± 5.94 to 44.16 ± 1.98 
minutes and the AUC increased (about 100-fold) from 12.45 ± 1.25 to 3695 ± 315 ng/mL•h. 
Three-dimensional (3D) spheroid culture with human hepatocarcinoma cells confirmed the 
results of the rat pharmacokinetic studies. Furthermore, studies using rat liver homogenate 
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revealed that the AuNPs directly inhibited liver xanthine oxidase and can explain the dramatic 
improvement of the stability of 6-MPR-AuNPs compared to 6-MPR alone.  
Chapter three examines the brain penetration of 6-MPR-AuNPs. Using whole-body 
fluorescence imaging and brain distribution experiments, we present compelling animal data that 
demonstrate brain uptake of 6-MPR after conjugation to AuNPs. We report on the biodistribution 
of fluorescein isothiocyanate-labeled 6-MPR-AuNPs (FITC/6-MPR-AuNPs) in rats. Compared 
to the control groups, the fluorescence intensity of rats injected with FITC/6-MPR-AuNPs was 
highest in the brain and cerebrospinal fluid (CSF). Tandem to these findings, we also observed 
that the AUC0.083-0.75h of CNS and plasma were respectively 5.3 and 142-fold higher in rats 
injected with 6MPR-AuNPs compared to rats given 6MPR alone. Correspondingly, the 6-MPR 
clearance decreased from 6076 ± 412 to 41.88 ± 3.24 mL/min/kg. Finally, transmission electron 
microscopy (TEM) of brain specimens provided further direct evidence that 6-MPR-AuNPs 
penetrated the intact BBB and was distributed into cerebral parenchyma and neuronal cells.   
In chapter four, we use dopamine-conjugated AuNPs (DA-AuNPs) to overcome the poor 
brain permeability of dopamine (DA). In addition, we use receptor binding studies to address the 
central question of whether or not a drug conjugated to AuNPs will lose its efficacy. Competitive 
binding studies using human dopamine receptor whole cells revealed that the binding affinity of 
DA-AuNPs was 10-fold higher than free dopamine. Also, rat ex vivo binding studies showed that 
DA-AuNPs compared to control groups had the strongest affinity to central D2R, producing 
receptor occupancy(RO) approaching 100% at 1uM dose. Free dopamine achieved only 80% 
occupancy at 1uM. We investigated the effect of AuNP size on the binding affinity of dopamine, 
and found that the RO of 5, 15, and 50 nm DA-AuNPs were respectively 90%, 60%, and 20%, 
whereas 100 and 200nm NPs had RO of only 5%. Furthermore, TEM images of rat brain striata 
provided evidence that DA-AuNPs indeed penetrated the BBB and was transported into the brain 
parenchyma. 
Finally, in chapter five, key findings of this thesis are summarized and perspectives on 
future research into brain drug targeting and nanotherapeutics are presented.  
 
 
 
 
  1  
 
 
CHAPTER 1 
GENERAL INTRODUCTION 
1.0 BACKGROUND 
 
1.1 Burden of neurological disorders 
 
One out of every three individuals will experience a diagnosable mental and neurological 
disorder (MND) during their lifetime. 
1,2
 Despite significant advances in the field, MNDs remain 
a critical unmet medical need of this century. MNDs comprise a range of central nervous system 
conditions such as Alzheimer‘s, multiple sclerosis, Parkinson‘s disease, diabetic neuropathy, 
insomnia, migraine, attention deficit hyperactivity disorder, major depressive disorder, 
schizophrenia, bipolar disorder and epilepsy, that negatively impact mood, behavior, brain 
function, and cognition. CNS disorders represent five of the top ten causes of disability and 
constitute greater than 20% of total healthcare spending. The global market for CNS drugs has 
grown to $78 billion in 2010, from $36.8 billion in 2002 and is expected to rise to $82 billion in 
2015.
3
  The return on research dollars is low (4.5%) across all therapeutic areas, only second to 
the combined profits of anesthetics and analgesics (Figure 1-1-1). An aging population along 
with an increase in life expectancy is expected to increase the incidence of CNS disorders.
4
 
Chronic neurological disorders such Alzheimer‘s, Parkinson‘s disease, and the sequelae of 
stroke, affect older adults disproportionately and contribute to disability, diminish quality of life, 
and increased healthcare costs. Stroke and Alzheimer‘s afflict 30% and 20%, respectively, of 
persons over 65 years. For Alzheimer‘s, this rises to 49% of people ages 80 years or more.5 
Alzheimer‘s and Parkinson‘s alone, collectively affect approximately 40 million people 
worldwide and is expected to rise steeply to 115 million by 2050 with an annual cost exceeding 
$375 billion.
6,7  
1.2 Challenges in developing CNS drugs  
 
Recent advances in biotechnology and pharmaceutical sciences have greatly expanded 
the number of new drug candidates that are being developed for the treatment of CNS disorders. 
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Despite this, the development of new medicines to treat diseases of the CNS is one of the most 
challenging undertakings of today‘s biopharmaceutical industry. CNS drugs take on average 40-
50% longer to market than non-CNS drugs. CNS drugs have a higher attrition rate, 15% 
compared to 7%, on average, compared to other therapeutic areas.
8
 For drugs involving new 
mechanisms of action, the success rate is very low (Figure 1-1-2).  
The high risk of failure for new CNS drugs is linked to the extraordinary complexity of 
the anatomy and physiology of the human brain, and its pathologies. Part of the problem resides 
in the incomplete understanding of the underlying pathophysiology and drug targets of most 
CNS disorders, including multiple sclerosis, Alzheimer‘s, Huntington‘s, and Parkinson‘s disease.  
Another persisting problem is identifying the dose and schedule which are both efficacious and 
safe for patients. This difficulty is further aggravated if the drug candidate has a narrow 
therapeutic window and a validated biomarker is not available. 
9
 Further complications are 
presented in the many hurdles that a molecule has to overcome between administration and 
reaching the target site of action within the CNS. Drug concentration in the brain depends on 
several factors such as the free plasma concentration, drug half-life, protein binding and 
distribution within the brain, efflux, and the continual drainage of CSF and brain interstitial 
fluid.
10
 Last and most importantly, the vasculature of the brain which forms the BBB serves as an 
obstacle to the entry of potential new CNS drugs into the brain. More than 98% of all new CNS 
drug candidates fail because they cannot cross the BBB in sufficient amounts to exert 
pharmacological effect.
11,12 
Efforts to design CNS drugs that overcome poor brain uptake, either by manipulating 
drug chemical properties, or cloaking drug properties in a delivery carrier or promoiety, have 
proven  inadequate.
13
 Therefore, there is need for new and effective CNS drug delivery systems 
that can circumvent the BBB in sufficient quantities. 
14,15
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Figure 1-1-1. R&D costs and returns by Therapeutic Category. DiMasi, J.A.; 
Grabowski, H.G.; Vernon, J. Drug Information Journal, 38, 211–223, 2004; 
Therapeutic area influences drug development costs. Frantz, S. News and 
Analysis: Nature Reviews Drug Discovery 2004, 3, 466   
 
Figure 1-1-2. Probability of Success for New Mechanisms. Adapted from: 
Kola and Landis, Nature Review Drug Discovery, 2004 (3):711-715 
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2.0 BARRIERS OF THE CENTRAL NERVOUS SYSTEM 
 
The CNS is separated from the peripheral blood circulation by physiological barriers 
which regulate movement of solutes from blood into the brain and provide a fully autonomous 
milieu for cells within the CNS. These barriers ensure a constant supply of nutrients and removes 
waste products from the CNS.
16
  However, the CNS barriers also prevent access to cerebral 
targets for many useful drug molecules circulating in the blood stream. The three major 
independent barriers within the CNS are the BBB (Figure 1-2-1a), blood-CSF barrier (BCSFB) 
(Figure 1-2-1b) and arachnoid barrier (Figure 1-2-1c). 
17,18
 The fetal CSF–brain barrier (Figure 1-
2-1d) and adult ependyma are also important (Figure 1-2-1e). Other interfaces with blood and 
neural tissues are the blood-retinal barrier and the nose-brain barrier. 
19,20
 The most important 
transport interface of CNS is however the BBB.  
2.1 Blood-brain barrier 
 
Paul Ehrlich (1885) and his student Edwin Goldmann (1913) provided the first 
experimental evidence of the existence of a barrier between the blood and the brain, which is 
today known as the BBB. The term ―Blut-Hirn-Schranke‖ or blood-brain barrier was first coined 
by Lewandowsky. In 1941, Broman proposed that it was the cerebral capillary endothelial cells 
that contribute the physical barrier function of the BBB and not the astrocytic end feet. This was 
supported by electron microscopic cytochemical studies performed in 1967 by Reese and 
Karnovsky.  
The current understanding is that the BBB is formed by cerebral endothelial cells sealed 
together by a very complex network of tight junctions (arrowhead). The BBB is not uniform 
throughout the brain because the capillaries in the circumventricular organs are fenestrated. The 
permeability of BBB is modulated by autocrine and paracrine secretions from several types of 
cells, such as the pericyte, astrocyte, and neurons
21
. The downside of the tightly controlled BBB 
is that it also limits the transport of therapeutics into the brain. Approximately 98% of the small 
molecule drugs and nearly 100% of the large molecule (e.g. peptides, proteins and nucleic acids) 
cannot substantially cross this barrier. 
22
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2.2 Blood-cerebrospinal fluid 
 
The blood–CSF barrier (BCSFB) separates choroid plexus blood vessels from CSF and is 
functionally and morphologically different from the BBB. The BCSFB originates from the tight 
epithelia cells of the choroid plexus in the ventricles rather than the endothelial cells lining the 
brain capillaries as is the case of the BBB. Unlike the capillaries that form the BBB, choroid 
plexus capillaries are fenestrated, forming a nonrestrictive barrier
23
. Notwithstanding its 
permeability, the blood–CSF barrier does not significantly increase the penetration of drugs into 
the brain. The epithelial cells have apical tight junctions towards their apical surface that restrict 
intercellular passage of molecules. Also the surface area of the BCSFB is ca.5000 times less than 
the BBB
24
.  Additionally the BCSFB faces the CSF, not blood, and therefore, the BCSFB is not 
as important an influx barrier for CNS drugs as the BBB. Therefore, the BBB is generally 
viewed as having a greater role than the BCSFB in the delivery of CNS medications to the brain.   
2.3 Arachnoid barriers  
 
The arachnoid barrier is formed by the epithelium of the meninges and forms the physical 
barrier between CSF-filled subarachnoid space, dura mater and overlying structures. The 
arachnoid barrier is the least studied and structurally most complex of all the brain barriers. The 
blood vessels of the dura are fenestrated and provide little barrier function. However, the outer 
cells of the arachnoid membrane have tight junctions (arrowheads) and this cell layer is believed 
to form the physical barrier between the CSF-filled subarachnoid space and overlying structures. 
Finally, the blood vessels in the arachnoid and on the pial surface have tight junctions with 
similar barrier characteristics as cerebral blood vessels.  
2.4 Cerebrospinal fluid–brain barrier and ependyma 
 
The CSF–brain barrier, a barrier between the CSF and brain parenchyma, has been shown 
to be a functional barrier present only in early fetal development.  In early development, the 
neuroependymal cells are connected to each other by strap junctions (open arrowheads) that are 
believed to form the physical barrier restricting the passage of larger molecules such as proteins 
but not smaller molecules such as sucrose. During later development, the neuroependymal cells 
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flatten and lose their strap junctions. The adult ventricular ependyma, therefore, does not restrict 
the exchange of molecules, at least as large as proteins, between CSF and brain.  
 
 
 
Table 1-1: Landmarks in the understanding of BBB and development of CNS drug therapy
25,26
  
 
1885 First lumbar puncture to administer cocaine for anesthesia 
1885 Concept of BBB indicated by the observation that dyes injected into the vascular system were 
rapidly taken up by all the organs except the brain. 
1900 Coining of the term ‗‗blood–brain barrier‘‘ to describe the phenomenon. 
1913 BBB observed to be decreased in the choroid plexus. 
1920 Intracerebral distribution of various substances administered systematically was observed. 
1927 First injections into the cerebral circulation: contrast materials for cerebral angiography. 
1940 Description of vertebral venous plexus and its connection to blood vessels of the brain laid the 
anatomical basis for use of epidural venous injection for drug delivery to the CNS. 
1940s Tor Broman of Goteborg, Sweden showed that the anatomical substrate of the BBB was the 
brain capillary wall. This was confirmed by electron microscopy a quarter century later. 
1941 Opening of the BBB by pharmacological means. 
1947 Stereotactic equipment for guided placement of instruments at selected targets in the depth of 
the brain for the treatment of movement disorders. 
1950s Electron microscopy used to show lack of extracellular fluid compartment between glia and 
neurons and this was given as explanation for why substances do not enter the brain. 
1954 Injection of a mixture of procaine and alcohol into the globus pallidus of the brain for 
treatment of movement disorders. 
1967 Electron microscopy confirmed brain capillary wall to be the BBB. 
1973 First injection of a therapeutic substance (diazepam) into the carotid arteries. 
1978 First implantable pump for intrathecal and intraventricular injection of morphine. 
1980s Studies in molecular biology of the BBB. Cloning and sequencing of glucose transporter gene. 
1990s Further development of direct injections of therapeutic substances, including biologics (e.g., 
gene therapy), into the brain, and development of strategies to overcome the BBB. 
1995 Use of nanoparticles for drug delivery across BBB. 
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Figure 1-2-1. Schematics of the sites of the barrier interfaces (indicated in orange) in the adult 
and developing brain. Saunders, N. Trends Neurosci. 2008, 31(6):279-86. 
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3.0 STRUCTURE AND FUNCTION OF THE BLOOD-BRAIN BARRIER 
 
3.1 Blood-brain barrier 
 
 
The blood-brain barrier is mainly formed by the endothelial cells surrounding the brain 
capillaries, although other cell types, such as pericytes, astrocytes, and neuronal cells contribute 
to the formation and maintenance of a functional BBB in the CNS. 
27,28
 The endothelial cells are 
completely covered by a basal lamina. The pericytes are embedded within the basal lamina and 
this covers about 20-30% of the endothelial cells. The basal lamina is surrounded by astrocyte 
end-feet
29
.  
The total capillary length of the BBB is 650 km. Every cubic centimeter of cortex 
contains the amazing sum of 1 km of blood vessels and the surface area is ca. 12 m2 or 100–150 
cm2/g brain
30
. The luminal diameter of brain capillaries is 3 mm (mean distance 40 mm) and the 
capillary volume is 1 ml or ca. 11 ml/g brain. Cerebral blood flow has a transit time through the 
brain of only 5s. The distance between luminal and abluminal membranes of endothelial cells is 
only 200 nm, this allows substances to cross the endothelial cells and enter the brain parenchyma 
within a short time
31,32
.  
The BBB endothelial cell (BCEC) differs from endothelial cells in the rest of the body by 
the presence of tight and adherens junctions between the cells, lack of fenestrae, low frequency 
of pinocytic vesicles, and increased numbers of mitochondria
33
.There is also high enzymatic 
activity in the cells forming the BBB, which can efficiently metabolize bioactive molecules 
before they cross the BBB and gain access to the brain parenchyma
34
. Furthermore, BBB 
endothelial cells express several transporter proteins, including P-glycoprotein (P-gp), multidrug 
resistance associated proteins (MRPs), GluT1, LAT1, the monocarboxylic acid transporter 1 
(MCT1), cationic amino acid transporter and the adenosine transporter (CNT2), which affect the 
transport of molecules into and out of the CNS. 
35,36  
Figure 1-3-1 represents the schematic 
illustration of BCECs and associated structures.    
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3.2 Pericytes 
 
Pericytes are undifferentiated, contractile connective tissues that develop around capillary 
walls and share the basal membrane with brain capillary endothelial cells. There is 
approximately one pericyte for every three endothelial cells. 
37,38  
Pericytes play a regulatory role 
in brain angiogenesis, structural differentiation of the brain endothelial cells, and formation of 
endothelial tight junctions. They also contribute to the microvascular vasodynamic capacity and 
structural stability. 
39
 Additionally, cerebral pericytes express several enzymes, such as 
transpeptidase and aminopeptidase, therefore constituting a major component of the metabolic 
BBB.
40,41
 It has also been suggested that cerebral pericytes have phagocytotic potential.
42
 
 
3.3 Astrocytes 
 
Astrocyte cells occupy approximately 99% of the abluminal surface of the brain capillary 
formed by the endothelial cells and are attached to a basement membrane.
43
 Astrocytes are 
characterized by large nuclei and thick cytoplasmic appendices with cap-like structures known as 
endfoot. However, endfoot processes are not sealed to each other and small gaps between the 
astrocytes allow passage of large and hydrophilic molecules. Although astrocytes do not take 
part in the formation of the physical barrier of the BBB, they are important in the development 
and maintenance of the BBB. Astrocytes secrete a range of growth factors and cytokines that 
strongly contribute to the BBB phenotype of endothelial cells, leading to tighter tight-junctions, 
and the expression of several transporter proteins (e.g. LAT1, GluT1 and P-gp) in the brain 
endothelial cells. 
44
 Moreover, the expression of several enzymes at the BBB is induced by 
astrocytes. Therefore, astrocytes can play a major role in the BBB metabolism.
45
  
 
3.4 Tight junctions 
 
The most important factors responsible for the restriction of the paracellular diffusion 
across the BBB are the fused junctional complexes which are present between endothelial cells.
46
 
Tight junctions are large, multiprotein complexes and the structure of the tight junction in the 
BBB has been found to be the most complex of all such entities in the entire vasculature of the 
body.
47
 The tight junctions between adjacent endothelial cells are 50–100 times tighter than those 
encountered in peripheral endothelium.
48
 In addition to sealing the paracellular route across the 
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BBB, tight junctions are responsible for the polarization of the endothelial cells, which results in 
non-uniform distribution of transporters between the luminal and abluminal membranes.
49
 In 
addition to tight junctions, brain capillary endothelial cells are joined by adherens junctions 
located near the basolateral side of the endothelial cells. Tight junctions and adherens junctions 
are both needed to form the BBB. 
50
  
 
 
 
 
 
Figure 1-3-1 (a) The BBB is formed by 
endothelial cells of the cerebral 
capillaries. The endothelial cells 
interact with basal lamina, astrocytes, 
and pericytes to form a functional 
BBB. (b) Cerebral endothelial cells 
form complex tight junctions (TJ), and 
adherens junctions (AJ). The presence 
of intracellular and extracellular 
enzymes such as cytochrome P450 
endows the BBB with metabolic 
activity. Specific receptors and efflux 
transporters are also involved in brain 
transport. Cecchelli, R. Modeling of the 
blood-brain barrier in drug discovery 
and development. Nature Review Drug 
Discovory 2007, 650-661. 
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4.0 CENTRAL NERVOUS SYSTEM DRUG DELIVERY     
 
 
Despite the fact that the brain is highly perfused by capillaries, the entry of molecules 
from blood to brain is governed by the impervious BBB. Drug permeability of the BBB is 
dependent on a number of parameters such as molecular weight (MW), lipophilicity, pKa, 
hydrogen bonding as well as biological factors. High molecular weight and hydrophilic drugs 
tend to fail as CNS drugs because of their poor ability to cross BBB.
51
 Paracellular transport of 
hydrophilic molecules is restricted by the tight junctions present between brain endothelial cells. 
On the other hand, lipid-soluble molecules with molecular weights below 400Da are able to 
cross by transcellular diffusion, provided that they are not substrates for efflux transport system. 
Only a few brain diseases consistently respond to small lipid-soluble molecules.
52
 
 
4.1 Methods for overcoming poor brain uptake of drugs 
 
Several creative methods have been used to get drugs into the brain. These involve direct 
injection into the brain, using nerves innervating the nasal passages, and opening of BBB tight-
junctions. Other methods make use of known endogenous brain transport mechanisms. 
Transcellular diffusion, carrier-mediated transport, paracellular transport, adsorptive endocytosis 
and receptor-mediated endocytosis can transport drugs across the BBB (Figure 1-4-1). Targeting 
ligands, monoclonal antibody and small peptide-vectors or nanoparticles are already being used 
to enhance receptor-mediated transcytosis of drugs into brain. These methods have limitations 
which will be discussed below. As such, new brain delivery strategies are needed.
53
 
 
4.1.1  Modifying physicochemical properties of CNS drugs  
 
Passive diffusion across the BBB is believed to be the most common mechanism of CNS 
drug uptake. However, the importance of transporter mediated brain uptake may be 
underestimated. 
54
  Passive diffusion can occur either between the cells (paracellular) or through 
the cells (transcellular), depending on the physicochemical properties of the solutes. Tight 
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junctions restrict paracellular transport across the BBB, therefore passive diffusion is restricted 
to a few molecules which have optimal physicochemical properties. 
A simple approach to increase the CNS entry of a polar molecule involves masking the 
polar functionalities. In practice, lipidization through lipophilic drug analogues often results in 
diminished therapeutic effect, due to decreased activity or increased toxicity of analogues. 
55
 
However, lipidization through prodrugs (the so-called chemical drug delivery system) offers the 
possibility for a more efficient CNS delivery of polar drugs without compromising their 
pharmacological effect or safety. Prodrugs, being more lipophilic than the parent drug, enter the 
CNS more readily, and are then converted back to the parent drug within the CNS. However, 
lipophilic prodrugs share some problems with lipophilic drug analogues which limit the utility of 
this approach. Lipophilic modifications can lead to an increase in molecular weight of the drug, 
thereby reducing the diffusion through biological membranes. Prodrug lipidization increases 
permeation across all other biological membranes in the body, leading to marginal increase in 
brain uptake of the drug, even though the BBB permeability is greatly enhanced.
56
  Additionally, 
high BBB permeability due to increasing lipid solubility is offset by a correspondingly high 
plasma protein binding which reduces the free fraction of drug needed to provide the driving 
force across the BBB. Non-specific binding in the brain also exaggerates the distribution volume 
of drugs in the brain parenchyma, which sustains the blood to brain concentration gradient.
57
 
However, as only the free fraction of the drug is effective, the high brain uptake due to the non-
specific brain tissue binding is futile.  
 
4.1.2 Invasive delivery methods 
 
Invasive delivery circumvents the BBB, resulting in high drug concentrations and half-
life in the brain. This approach reduces systemic drug concentrations and side effects, but 
inevitably requires extremely invasive surgical procedures. Intracerebroventricular (icv) 
injection, intracerebral (ic) injection, direct implantation of biodegradable vehicles inside brain 
parenchyma and the use of permeability enhancers to disrupt tight-junctions are the main types 
of invasive delivery methods.
58
 During icv injection, the drug is injected into the CSF. The drug 
has to diffuse from the CSF to the brain parenchyma via the ependymal barrier. Because of the 
rapid turnover of the CSF and the slow diffusion rate of drugs, generally only a small amount of 
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the drug reaches the brain parenchyma. However, icv injection can be effective when local 
administration of drugs is needed (e.g. treatment of brain tumors) or when the target receptor lies 
in close proximity to the ependymal surface.
59
 
Another invasive injection method is ic injection. Here drugs are injected directly into the 
brain parenchyma using convection-enhanced delivery (CED). CED relies on a continuous 
infusion to drive the drug throughout a larger region of tissue at a sufficiently high rate to 
achieve an additional convective transport of drug. Injectable poly(lactic-co-glycolic acid) 
(PLGA) and polylactic acid (PLA) microspheres have been widely used to achieve sustained 
release of drugs at the desired site of the brain. The microspheres are delivered by minimally 
invasion stereotaxic injection technique.
60
 Brain implants of 1,3-bis(2-chloroethyl)-1-
nitrosourea-loaded biodegradable polymer wafers (Gliadel®) has demonstrated a novel approach 
to circumvent the BBB and been tested in Phase III clinical trials, leading to an extensive 
research interest in this area.
61
 Overall, ic injections and drug-releasing implants have turned out 
to be ineffective because the steady turnover of brain extracellular fluid carries the drug away 
from the injection site.
62
 
Osmotic disturbance of tight-junctions allows drugs to be delivered to the brain by 
manipulating the BBB tight-junctions. This is achieved by infusion of a hypertonic agent (e.g. 
mannitol 25%), bradykinin or other cytokines (e.g. histamine) into the carotid artery. The BBB 
opens for about 30 minutes, presumably by shrinking the endothelial cells and disrupting the 
tight junctions, allowing the drug to freely diffuse into the brain.
63
 However, opening of the BBB 
makes it possible for harmful substances such as neurotransmitters and circulating toxins to enter 
the brain as well.
64
 Therefore, tight-junction disturbance is restricted mostly for use in terminally 
ill patients with brain tumors. 
4.1.3 Intranasal delivery 
 
Intranasal drug delivery bypasses systemic circulation and the BBB by providing direct 
access to the brain via the olfactory and trigeminal nerves innervating the nasal passages.
65
 
Intranasal delivery has been successfully explored for the delivery of small lipophilic molecules 
like cocaine and morphine. It provides a noninvasive alternative to CNS delivery. The exact 
mechanism of brain entry via the nasal route remains unclear, but the main technical concern is 
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increasing the residence time in the nasal cavity for optimal nasal drug absorption. Bioadhesive 
formulations with active targeting to the olfactory region, as well as controlled release 
preparations have been investigated extensively for this purpose. Bioadhesive polymer 
formulations (prepared by low esterified pectins) have the requisite gelling and viscosity 
properties, and are being used in controlled-release vehicles for intranasal delivery.
66
  
 
4.1.4 Active transport 
Active targeting of the BBB represents a promising non-invasive strategy for improving 
drug delivery to brain. It involves various influx transport systems expressed within the cerebral 
endothelium. These transport systems include carrier-mediated transport, receptor-mediated 
endocytosis and adsorptive-mediated endocytosis.  
 
4.1.5 Receptor-mediated transport    
 
Large molecules and particles such as antibodies, lipoproteins, insulin, transferrin, leptin 
or nanoparticles can be transported into the brain via receptor-mediated transport (RMT).
67
  
Receptor-mediated drug delivery takes advantage of endogenous transport systems by directly 
coupling a targeting ligand to the drug. Examples include L-DOPA and gabapentin (using amino 
acid transporter, LAT), mepyramine and lidocaine (using the organic cation transporter, OCT) 
and glycosylated morphine (using the glucose transporter, GLUT-1).
68
  
One widely characterized BBB receptor is the insulin receptor. Unfortunately, high doses 
of insulin are required for efficacy, making it an unsafe targeting ligand. Such high doses of 
insulin have the potential to result in hypoglycemia. Therefore, antibodies including the murine 
83-14 monoclonal antibody are being studied for targeting.
69
 Other receptors are low density 
lipoprotein receptor (LDLR) and LDLR-related protein (LRP). These receptors can bind multiple 
ligands, including low-density lipoprotein (LDL), lactoferrin and apolipoproteins.  
The most studied receptor used for BBB targeting is the transferrin receptor (TfR). In 
contrast to apo-transferrin, the natural TfR ligand (holo-transferrin) has much higher affinity. 
However, the application is limited because endogenous levels of transferrin are high, resulting 
in nearly saturated transferrin receptors.
70
 A strategy to circumvent endogenous competition of 
transferrin is to use antibodies directed against the TfR. The most studied TfR-targeted antibody 
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is the mouse anti-rat monoclonal antibody OX26, which binds to an epitope of the TfR rather 
than to the transferrin binding site. The monoclonal antibodies (MAbs) serve as a ―molecular 
Trojan horses‖ to ferry drugs across the BBB.71    
4.1.6 Adsorptive-mediated endocytosis 
 
Large molecules such as antibodies, proteins, and structures such as nanoparticles can be 
transported into the brain by adsorptive-mediated endocytosis.
72,73
  Adsorptive-mediated 
endocytosis is initiated by non-specific electrostatic interactions between polycationic substances 
and negatively charged endothelial cell membranes. Conversely, RMT systems are selective for 
BBB transport and require initial binding of ligand to receptor on the BBB endothelium.
74
 
Adsorptive-mediated endocytosis is rarely used for drug targeting to the brain, because 
this process also occurs to a large extent in other organs of the body (e.g. liver, kidneys), thereby 
decreasing brain specificity.
75
 Furthermore, the cationic charge may lead to aggregate formation 
in circulation. However, significant brain targeting using adsorptive-mediated endocytosis has 
been accomplished using cationized human serum albumin(cHSA) as a transport vector coupled 
to 3H-biotin.
76
 
4.1.7 Carrier-mediated transport 
 
Carrier-mediated transporters facilitate the delivery of hydrophilic molecules and 
nutrients such as glucose, amino acids, and purine bases to the brain.
77,78
  Since carrier-mediated 
transport systems are typically small and stereospecific, they are not particularly amenable to the 
transport of large-molecule therapeutics. Carrier-mediated transport relies on molecular carriers 
present at both the apical (blood) and basolateral (brain) membranes of the BBB. Drugs may be 
modified such that they closely mimic the endogenous carrier substrates and can be taken up and 
transported into the brain. Making chemical modifications in such a way that the drug can be 
recognized by specific transporters, but still maintain therapeutic efficacy, has proven to be very 
challenging.
79
 Furthermore in carrier-mediated transport, the drug has to compete with 
endogenous substrates for the carriers. Finally the efficiency of receptor-mediated delivery is 
generally quite low, as the use of a vector in this manner results in only one molecule being 
delivered per transferrin receptor.
80
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4.1.8 Active efflux transport 
 
The transcellular brain uptake of some small lipophilic solutes is lower than expected 
given their lipophilicity. The low brain uptake of lipophilic solutes is often due to active efflux 
proteins, such as P-glycoprotein (P-gp), ABC transporters, Multidrug Resistance-Associated 
Protein (MRP), organic anion transporter (OAT) and others that remove solutes from endothelial 
cells. 
81,82
  The impact of efflux proteins on the brain uptake of CNS drugs is significant since 
these transporters have a broad range of substrates. Encoded by the multidrug resistance protein 
1 (MDR1), P-gp is localized to the luminal membrane of endothelial cells and pumps 
amphipathic organic cations or neutral compounds out into the capillaries. MRP and OAT pump 
anions out of the CNS as efflux proteins. 
83,84
 Transport across the BBB may therefore be 
increased by inhibiting certain efflux transporters. Inhibition of the Pgp-dependent multidrug 
resistance functions could improve brain permeability and maintain CNS drug concentrations. P-
gp is one of the most studied active efflux transporters. 
 
 
Figure 1-4-1. Transport mechanisms at the BBB. Abbott, N.J.; Romero, I.A. Transporting 
therapeutics across the blood-brain barrier. Mol Med Today 1996, 2,106–113. 
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5.0 NANOMEDICINE 
 
5.1 Definition and general description 
 
Nanotechnology describes materials and devices that have a functional organization in at 
least one dimension on the nanometer scale, ranging from a few to about 100 nanometers (figure 
1-5-1). 
85
 The reason for the tremendous potential of nanotechnology in biology and medicine 
stems from their ability to interact with cells at the molecular level because of their size. 
86
 
Furthermore, nanoscaled materials exhibit interesting bulk mesoscale chemical, biological and 
physical properties that are not possessed by the molecules alone. Additionally the small size and 
large surface area of nanocarriers allow them to deliver more drug molecules to disease targets 
than traditional methods.  
The past twenty years have seen a convergence of nanoengineering and biomedical 
research, giving rise to many new technologies and ideas in medicine. Nanotechnology is poised 
to drive significant improvements in disease diagnosis and treatment. Various research teams 
have demonstrated use of nanomaterials for accurate, sensitive, rapid, and often multiplexed 
detection of disease markers. 
87,88
 As well, genome and proteome knowledge gained from disease 
biology has been combined with micro- and nanotechnology in an attempt to discover accurate 
methods for diagnosis and surveillance.
89
 Nanotechnology will also allow new therapeutics to be 
developed. 
90,91
 Therapeutic biomolecules may be engineered onto a nanoparticle surface to alter 
a disease‘s molecular target. 92 Liposomes, solid lipid nanoparticles, nanogels, dendrimers, 
albumin nanoparticles, iron-oxide particles, and polymeric nanoparticles have been extensively 
studied for CNS drug-delivery and diagnostics. 
93
 Figure 1-5-2 summarizes the different types of 
nanoparticles used in drug delivery.       
 
5.2 Nanotechnology brain delivery  
 
Interventional methods that open the BBB to deliver drugs to the brain have their 
drawbacks. Non-specific opening of BBB by chemical agents also allows the entry of toxins and  
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unwanted molecules.
94
 Similarly, invasive techniques such as the use of intracerebral injections 
require intrusive neurosurgery. Additionally, significant diffusion of the drug away from the 
injection site occurs, rendering the therapy ineffective.  
Nanoparticle mediated drug delivery provides a superior alternative to surgery or altering 
BBB physiology. Nanoparticles remain intact as they cross the BBB and do not alter the BBB 
integrity. Also nanoparticle properties such as composition, surface charge, and particle size can 
be fine-tuned. Furthermore, targeting ligands, native carriers and receptors expressed at the BBB 
can be used for targeted delivery. For nanoparticle delivery, the drug is directly conjugated to a 
brain targeting ligand or adsorbed on the particle‘s surface through electrostatic interaction. The 
drug can also be encapsulated into nanoparticles which may then be coupled to a ligand on the 
outside of the particle, enabling BBB-impermeable compounds to enter the brain. 
95, 96 
 
5.2.1 Advances in nanoparticles CNS delivery  
 
In 2009 researchers demonstrated that iron oxide nanoparticles, when coated with 
polyethylene glycol-grafted chitosan and conjugated to chlorotoxin, crossed the BBB to target 
brain tumors in a genetically engineered mouse model. The researchers used magnetic resonance, 
biophotonic imaging and histologic analyses to show sustained retention of chlorotoxin in the 
tumors. Drug-conjugated iron oxide for diagnosis and treatment of a variety of tumor types in 
brain continues to gain attention.
97
  
Similarly, Gil et al. reported successful delivery of doxorubicin (DOX) across the BBB 
after intraveneous administration of novel quaternary ammonium beta-cyclodextrin (QAbetaCD) 
NPs. They showed that the 65-88 nm DOX-QAbetaCD NPs kill U87 cells as effectively as DOX 
alone, without destroying Bovine Brain Endothelial Cells. As a result, it has been suggested that 
QAbetaCD NPs are safe and effective brain delivery systems. 
98
 
Work carried out in the laboratory of Tosi (Modena, Italy) convincingly showed that 
poly-lactide-co-glycolide (PLGA) NPs engineered with glycopeptide (g7) was effectively 
delivered to the brain parenchyma of rats after i.v. administration.
99
 A dual-targeting drug carrier 
(PAMAM-PEG-WGA-Tf) was also recently developed based on the PEGylated fourth 
generation PAMAM dendrimer with Tf and wheat germ agglutinin (WGA) on the periphery, and 
DOX loaded in the interior. The 20 nm particles PAMAM-PEG-WGA-Tf efficiently inhibited 
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the growth rate of the C6 glioma cells, while minimizing cytotoxicity of DOX to the normal 
cells.
100
 
Over the last decade, there has been significant development involving receptor-targeted 
brain delivery with nanoparticles. Endogenous ligands like low-density lipoprotein (LDL), 
insulin, transferrin (Tf) and folic acid among others have been widely studied
101
.  Nanoparticles 
with covalently bound apolipoprotein E (apo E) or adsorbed apolipoprotein A-I (apo A-I) were 
reported to enhance brain penetration.  Tubocurarine, doxorubicin and amitriptyline when 
adsorbed onto polybutylcyano-acrylate nanoparticles coated with polysorbate-80, led to a 10-fold 
increase in its levels in brain. It is postulated that apolipoprotein-E (apo-E) adsorbs onto 
nanoparticles coated with polysorbates thereby causing endocytosis at the BBB. When the 
nanoparticles were not coated with surfactants, the particles remained in the blood vessels. 
102,103 
Despite these results, a number of weaknesses in these studies have been pointed out.   
Specifically PBCA is fairly toxic and it is well known that polysorbate-80 will cause BBB 
disturbance at intravenous doses as low as 3mg/kg.
104
 This may in fact explain the increase in 
brain drug concentration and the effect may be further enhanced when the nanoparticles are 
coated with polysorbate 80. Furthermore, the authors did not show that the integrity of BBB is 
maintained during treatment with the polysorbate 80-coated nanoparticles. 
Transferrin coupled to nanoparticles has also shown a significant increase in BBB uptake 
via the trasferrin receptor.
105
 However, the potential of OX26 (the monoclonal antibody against 
trasferrin) in crossing BBB has been presented by the Pardridge group in 1991.
106
 Monoclonal 
antibody known as OX26 recognizes an extracellular domain on the transferrin receptor that is 
distinct from the transferrin binding site, and does not interfere with endogenous transferrin 
binding. However, use of antibodies such as OX26 appears to be limited by several factors, 
including receptor saturation, low dissociation rate of the antibody, recycling of the receptor 
back to the blood, and hypersensitivity resulting in hyperimmunity against the foreign 
monoclonal antibody conjugated nanocarrier.
107
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5.3 Gold Nanoparticles 
 
5.3.1 Applications and general description 
 
Gold nanoparticles have a long history of being used in biomedical research. Perhaps 
owing to centuries-old fascination or to the variety of potential applications that can be imagined, 
gold nanoparticles have become one of the most common scientifically used nanomaterials. Gold 
nanoparticles can be synthesized by different protocols to have a variety of shapes and sizes. 
These include spheroids
108,109
, nanorods
110
, and many others.
111
 This matters because the 
properties of gold nanoparticles, that make them interesting and scientifically useful, result from 
their surface-to-volume ratio, their conductance band electron properties (surface plasmon), as 
well as interaction with their dielectric environment. All of these properties are determined by 
their size and shape. In this regard, an interesting use of gold particles is molecular sensing based 
on Raman spectroscopy, and enhancement of Raman signatures by nanoparticle surface 
plasmons.
112,113
 The striking and intense visible range absorbance resulting from their surface 
plasmon has been used in a variety of diagnostic and therapeutic applications.   
Finally, gold nanoparticles make an excellent model system for testing a wide variety of 
biological hypotheses. This is because they are chemically stable, biocompatible and easy to 
synthesize and modify. 
114,115
 As well, the breadth of sizes and shapes that can be synthesized for 
a single material make it possible to test how these design parameters impact the interaction of 
nanomaterials and biological systems.   
 
5.3.2 Relevant research 
 
Acute toxicity studies in mice injected with 2.7g/kg of 1.9nm AuNPs showed no signs of 
adverse events (LD50 was 3200mg/kg) after a year.
116
 Biodistribution studies using different 
sizes of AuNPs show that 4 nm AuNPs accumulate in brain, kidney, liver, spleen and lungs after 
oral administration to mice.
117
 In one study the 10 nm AuNPs were found in liver, spleen, 
kidney, testis, thymus, heart, lung and brain of rats following an i.v. injection, the 50 and 250 nm 
particles were only present in liver and spleen.
118
 Another study reported extensive 
biodistribution of 15nm AuNPs compared to the 50, 100 and 200nm particles.
119
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Direct comparison of these studies is difficult because of differences in the experimental 
designs. However it appears that there is a trend toward high biodistribution for smaller (4–
15nm) particles compared to their larger (>50 nm) counterparts. Interestingly, using Cysteine 
coated (CdSe)ZnS quantum dots(QDs), Choi et al. have also reported that hydrodynamic 
diameters less than 5.5 nm provide optimal renal excretion of QDs (Figure 1-5-3).
120
 The authors 
also reported that zwitterion (cysteine) or neutral (polyethylene glycol) coatings prevented liver 
uptake unlike charged particles. These findings suggest that hydrophilic, near-neutral particles of 
less than 5.5 nm represent the optimal characteristics to guanrantee minimal RES uptake and 
high renal clearance of non-biodegradable nanoparticles. This work also establishes that particle 
size, rather than charge and surface chemistry most influenced the clearance of nanoparticles. 
Interestingly in addition to BBB permeation limitation, brain microvasculature endothelia 
also present an electrostatic barrier at physiologic pH. The negative electrostatic charge is 
created by surface expression and adhesion of the glycocalyx residues: proteoglycans, sulfated 
mucopolysaccharides, and sulfated and sialic acid-containing glycoproteins and glycolipids.
121
 
The anionic nature of the endothelium repels anionic molecules, and cationic molecules have 
been shown to occupy anionic areas at the BBB endothelium. Increasing BBB permeability, 
presumably by adsorptive transport or tight junction disruption by cationic molecules has been 
described.
122
  Cationized NPs have been shown to increase distribution to the cerebral 
parenchyma compared to anionic and neutral NPs, owing to this interaction.
123
   
In vitro experiments conducted by Podsiadlo et al. found that 5nm AuNPs bearing 6-
mercaptopurine riboside (6-MPR) significantly reduced the growth of K562 leukemia cells 
compared to free 6-MPR(Figure 1-5-4a). Using laser confocal microscopy, the authors also 
found that when cells were incubated at 37ºC (Figure 1-5-4b) with fluorescein isothiocyanate 
(FITC)-6MPR-AuNPs, there was a gradual increase in fluorescence inside the cells which was 
not observed for cells incubated at 4ºC (Figure 1-5-4c).
124
 This result points to active transport or 
endocytosis of AuNPs into cells.  
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Figure 1-5-1. Structures on the nanoscale and relative scale of nanotechnology. Nanoscale 
overlaps with that of biomedically relevant classes of biomolecules, viruses and small cells. 
www.nih.gov 
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Type Definition Schematic
Liposomes
Liposomes are vesicles composed of one or more bilayers of amphiphatic lipid 
molecules enclosing one or more aqueous compartments. 
Micelles
Micelles are self -assembling nanosized colloidal particles with a hydrophobic core 
and hydrophilic shell currently used for the solubilization of various poorly soluble 
pharmaceuticals.
Nanoemulsion
Nanoemulsions are emulsions with droplet size in the nanometer scale. Emulsion 
is a thermodynamically unstable system consisting of at least two immiscible 
liquid phases, one of which is dispersed as globules, in the other liquid phase, 
stabilized by the presence of an emulsifying agent.
Dendrimers
Dendrimer is a polymer in which the atoms are arranged in many branches and 
sub-branches along a central backbone of carbon atoms.
Metal colloids 
Metal colloids refers to a state of subdivision, that the molecules or polymolecular
particles dispersed in a medium have at least in one direction a dimension 
between 1 nm and 1µm, i.e. silver, gold,and iron oxide. 
Quantum dots
Nanoparticle that exhibits size-dependent electronic and optical properties due to 
quantum confinement.
Fullerenes, 
Carbon 
nanotubes
Fullerene: Closed cage structure having more than 20 carbon atoms consisting of 
three-coordinate carbon atoms. Carbon nanotube refer to a seamless tube 
constructed from graphene than can be either a single-wall or multi-wall carbon 
nanotube compromising multiple concentric tubes .
 
Figure 1-5-2. Drug Delivery Nanoparticles (courtesy of Sadrieh, N. Office of Pharmaceutical 
Science, CDER/FDA) 
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 %ID Urine                                                     %ID in carcass 
 
Figure 1-5-3. (a) Compositions of CdSe/ZnS quantum dots with DHLA (anionic), cysteamine 
(cationic), cysteine (zwitterionic) and DHLA-PEG (neutral) coatings.  (b) Plasma concentration 
(%ID/g) of different sizes of  99mTc-labeled quantum dots after intravenous injection into CD-1 
mice. (c) Renal clearance (blue curve) and carcass retention (red curve) of 99mTc-QDs of 
various hydrodynamic diameters 4 h after intravenous injection into CD-1 mice (Choi, H.S.; Liu 
W. Renal clearance of quantum dots, Nat Biotechnol. 2007, 25(10), 1165-70) 
 
 
 
 
 
Figure 1-5-4.  (a) Cell count of K562 leukemia cells after 72h of incubation with 6MPR (a) Laser 
scanning confocal micrograph of K-562 cells following incubation at 37 ºC with FITC-labeled 6-
MPR/Cys-Au NPs for (b) 0 hours, (c)16 hours (FITC: green, FM 4-64 membrane dye: red) 
(Podsiadlo, P. Langmuir 2008, 24, 568-574) 
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6.0 PROBLEM STATEMENT, OBJECTIVES AND SCOPE OF THESIS 
6.1 Problem Statement 
In recent years drug development has focused on optimizing drug-target protein 
interactions. This has lead to the development of large molecules that cannot cross the BBB. 
More than 98% of all potential new CNS drugs fail because they cannot cross the BBB to gain 
access to disease targets. 
125
 Therefore achieving BBB penetration remains a significant hurdle to 
successfully prosecuting CNS targets.  
As described in earlier sections of this thesis, several CNS delivery strategies have been 
attempted. However an effective brain delivery system is still lacking. The most effective 
method to-date involves direct injection of drug into the brain. Owing to the risks associated with 
surgery or altering BBB physiology, nanoparticle mediated-targeting is gaining enormous 
interest as an effective alternative to delivering drugs to the brain.  
Nanoparticle drug delivery systems typically involve direct coupling or coating of 
targeted BBB receptor ligands to nanoparticles. However the majority of targeted receptors are 
not only expressed on brain endothelial cells, but elsewhere in the body. As a result, it is difficult 
for high quantities of nanoparticles and their payload to reach the brain. Additionally, carrier 
transporters are stereospecific and few. Therefore, only a limited number of substances can 
potentially be delivered via carrier transporters. New targeting carriers are urgently needed to 
efficiently deliver drugs to the brain.  In this thesis we describe preparation, characterization and 
multimodal testing of novel, non-toxic, excretable small gold nanoparticles that can traffic drug 
molecules across the BBB into the brain parenchyma, without the need for BBB-receptor 
ligands. The approach relies on the unique properties of small gold nanoparticles to cross the 
BBB and interact with cells.  
6.2 Objectives and scope 
 
The primary objective of this thesis is to develop and evaluate the novel use of gold 
nanoparticles as a drug vector for effective delivery of drugs into the brain. However, BBB 
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penetration of drug molecules alone does not guarantee optimum brain delivery. The optimum 
CNS drug delivery system is nearly always the best compromise among competing 
physicochemical and physiological factors. Therefore, the second objective of this thesis is to 
evaluate the effect of gold nanoparticles on drug pharmacokinetics such as half-life, clearance, 
and plasma concentrations. These parameters are important to the development of proper CNS 
drug therapy. Finally in this thesis we address the central question of whether or not gold 
nanoparticles conjugated to a drug molecule will exhibit inferior receptor binding and potency, 
compared to the naive drug molecule. Additionally, this research provides a drug-delivery tool 
for testing future CNS drug candidates that otherwise could not be evaluated due to lack of BBB 
permeability. The research provides critical conceptual data for more advanced testing of 
AuNPs.  
6.2.1 Model compounds 
 
6-Mercaptopurine riboside is an antineoplastic agent used in the treatment of 
lymphoblastic leukemia (ALL), Inflammatory Bowel Disease (IBD) and other diseases.
126
 6-
Mercaptopurine riboside was however chosen as a model compound for this study because it has 
poor brain penetration. In addition, 6-MPR has the added complication of being rapidly 
metabolized by the liver enzyme xanthine oxidase. 6-MPR is however easy to detect by UV-
detector or mass spectrometry and its thiol functional group makes it easy to conjugate to gold 
nanoparticles. Finally, 6-mercaptopurine is a well established therapy for ALL. Therefore, 
enabling brain uptake of 6-MPR has the potential of advancing novel therapeutic uses in the 
treatment of brain cancer and leukemic meningitis.
127
  
Dopamine is a neurotransmitter that helps control the brain‘s reward and pleasure centers. 
Dopamine also regulates movement, emotional responses, and a number of other important 
physiological functions. Dopamine was chosen as a model compound for the receptor binding 
experiments in this thesis, because of its poor BBB penetration and for the crucial role dopamine 
plays in many CNS disease mechanisms.
128
 Dopamine has been implicated in the mediation of 
schizophrenia, depression, Parkinson‘s disease and others. Furthermore, the existence of 
dopamine-receptor binding is well understood and allows for quantitation of receptor binding.   
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CHAPTER 2 
 
GOLD NANOPARTICLES DRASTICALLY DECREASE CLEARANCE AND INCREASE 
THE HALF-LIFE OF CHEMOTHERAPEUTIC AGENT, 6-MERCAPTOPURINE 
RIBONUCLEOSIDE 
 
2.0 INTRODUCTION 
 
Innovations in cell and molecular biology, high throughput techniques and combinatorial 
chemistry have resulted in an explosive growth in the number of new drug candidates in 
discovery pipelines. Despite these advances, the increasing molecular complexity of drugs and 
biological targets have not resulted in a corresponding increase in the number of new drug 
applications. Recent breakthroughs in nanotechnology have provided new opportunities to 
deliver new chemical entities (NCEs) to inaccessible drug targets.
1
 
Polymeric nanoparticles (NPs)
2−4
 
 
and other nanoscale organic colloids, such as  
liposomes
5
, micelles
6,7
  and dendrimers
8,9
 can increase the solubility of hydrophobic molecules, 
alter release and biodistribution of drugs, enable targeting and increase drug therapeutic indices. 
10,11 
Much of the research, to date, has focused on organic nanoparticles. However similar to 
organic NPs, AuNPs can potentially benefit from the interactions of inorganic NPs with cells
12,13
 
 
and proteins.
14,15
 While knowledge exists that the inorganic core of NPs can extensively change 
protein conformation,
16,17
 these effects are still novel in the drug delivery field.  These properties 
may affect many aspects of drug delivery, but it would be particularly interesting to see their 
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effect on the in vivo pharmacokinetics of drug-conjugated inorganic NPs, which until now has 
not been undertaken.  
Considering the dramatic effects of inorganic NPs on enzyme activity,
18
  AuNPs 
influence on pharmacokinetics could be equally dramatic. Gold nanoparticles (AuNPs) have 
attracted considerable attention as a promising drug delivery and diagnostic platform. This is 
because AuNPs are chemically stable, biocompatible, easy to functionalize for specific targeting, 
and have special plasmonic properties.
19−22
  Work has also been done on better understanding the 
toxicity 
23 
and biodistribution of AuNPs.
24−26    
Antimetabolites, 6-MP and 6-MPR (Figures 2-1-1a and 2-1-1b) are widely used in the 
clinical treatment of acute lymphoblastic leukemia (ALL) and related diseases. The mechanism 
of action of purine antimetabolites essentially involves the conversion of mercaptopurine into 
cytotoxic 6-thioguanine nucleotide (6-TGN). 6-TGN is subsequently incorporated into the DNA 
or RNA of nucleated cells by hypoxanthine-guanine phosphoribosyl transferase (HGPRT) 
instead of the naturally occurring purine bases (Figure 2-1-2). 
27  
These events ultimately lead to 
cell death and are thought to be the source of the antineoplastic effects of mercaptopurines.  
Conventional therapies with mercaptopurines are however susceptible to enzymatic 
inactivation by hepatic xanthine oxidase (XO), resulting in short plasma half-life and large 
variability in cytotoxic efficacy.
28
  Inactivation involves methyltansferase catalysis of 
mercaptopurine to 6-methylmercaptopurine, and XO conversion to 6-thiouric acid.
29
 The 
importance of optimizing 6-MP therapy to maintain high systemic exposure is therefore critical 
to effective clinical management of ALL. 
              In this paper we decided to gain a better understanding of the potential effects of gold 
NP on the pharmacokinetics of 6-MP and 6-MPR. Using 2D and 3D cell cultures, liver 
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homogenate, and animal studies, we demonstrate that AuNP carriers drastically alter the 
pharmacokinetics of 6-MPR by inhibiting hepatic xanthine oxidase (XO) activity, which has not 
been observed for other nanoscale carriers of this drug. 
30,31 This study proposes a new and more 
effective paradigm for delivering 6-MPR using AuNPs (Figures 2-1-1c). To our knowledge, this 
is the first time such a delivery strategy to deliver 6-MPR has been proposed and evaluated. 
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Figure 2-1-1. Chemical structure of (A) 6-Mercaptopurine (B) 6-Mercaptopurine riboside  
(C) Schematic representation of 6-MPR-Au NP 
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Figure 2-1-2. Schematic of the metabolism of 6-mercaptopurine (6MP) and 6-mercaptopurine riboside 
(6MPR). 6-mercaptopurine nucleotides (6MPN); 6-thioguanine nucleotides(6TGN); 6-methyl 
mercaptopurine (6MMP); 6-methylmercaptopurine riboside (6MMPR); 6-methylmercaptopurine 
nucleotides (6MMPN); 6-thiouric acid (6TU); thiopurine methyltransferase (TPMT); hypoxanthine 
phosphoribosyltransferase (HPRT); xanthine oxidase (XO). 
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2.1 METHODS 
 
2.1.1 Materials 
 
6-Mercaptopurine riboside, 6-Mercaptopurine, trisodium citrate dihydrate, 
tetrachloroauric (III) acid trihydrate, sodium borohydride, L-cysteine and fluorescein 
isothiocyanate isomer I (FITC) were purchased from Sigma-Aldrich and utilized without further 
purification. Ultrapure water (Barnstead) with 18.2 MΩ-cm was used for all experiments.  
2.1.2 AuNPs synthesis  
 
Citrate stabilized gold nanoparticles were freshly prepared and used immediately for the 
synthesis of 6-MPR-AuNPs. Gold sol was prepared by sodium borohydride reduction of 
tetrachloroauric (III) acid solutions following previously reported methods
32−34
  with some 
modifications. Briefly, 5 mL of 1 w/w% tetrachloroauric (III) acid solution was diluted in 50 mL 
of ultrapure water and stirred for one minute. Next 2.5 mL of 3.4mM sodium citrate was added 
and the resulting solution was stirred for one minute. 5 mL of 0.075 wt% sodium borohydride 
was then added to the gold solution.  
2.1.3 6-MPR-AuNPs synthesis  
To prepare 6-MPR-AuNPs, 50 mL aqueous solution containing 12.5mg of 6-MPR was 
added to the reaction vessel containing gold sol, 30 secs after the sodium borohydride was added.  
Finally the solution containing 6-MPR-AuNPs was purified by centrifugation at 45000 rpm 
(190000 gr max) for 45 minutes. Following removal of the supernatant, the nanoparticles were 
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redispersed and the purification step repeated. The final precipitate was redispersed in 50 mL of 
sterile water for injection and stored at 4 °C until further use.  
2.1.4 Nanoparticle Characterization  
Transmission electron microscopy (FEI Tecnai, G2 Sphera) imaging was performed on  
6-MPR-AuNP solutions at 100,000 times magnification. Mean surface area and diameter of the 
particles were then determined using Image-Pro Plus software (Media Cybernetics). To prepare 
samples for TEM, 2-5 μL aliquots of the sample were placed onto carbon-coated formvar covered 
support grids and air-dried overnight in a protective environment. Representative images from 
samples at 100,000x were used to acquire sufficient (greater than 100) nanoparticle objects for 
image analysis. Images were processed to optimize particle segmentation. Statistics and frequency 
histograms were generated. The zeta potential of 6-MPR-AuNP was measured using Zetasizer 
Nano ZS, Malvern Instruments. Finally, High Pressure Liquid Chromatography (Agilent HPLC 
System) was used to determine the concentration of 6-MPR immobilized on the surface of AuNPs 
by digesting the gold colloids with potassium cyanide.  
2.1.5 Animal Studies  
Male Sprague-Dawley rats weighing on average 250-300 grams with surgically 
implanted vascular cannulas in the carotid artery and jugular vein were purchased from Charles 
River Laboratories (Willmington, MA). Rats were housed, one per cage, in an American Animal 
Association Laboratory Animal Care accredited facility and maintained under standard 
conditions of temperature (22 ± 2 ºC), relative humidity (50%) and light and dark cycles (12 
hours/12 hours). Rats were allowed to acclimate
 
to their environment for one week. Rats had 
access to food and water ad libitum throughout the study. Experiments were conducted according 
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to procedures approved by the Pfizer Global Research and Development Animal Care and Use 
Committee and complied with the NIH Guide for the Care and Use of Laboratory Animals.  
2.1.5.1 Pharmacokinetics Study 
Three male SD rats were each dosed with 6-MPR-AuNPs (5 mg/kg active) over 3 
minutes. As control, three male SD rats were each dosed with 5 mg/kg 6-MPR solution. All rats 
were dosed successfully via jugular vein cannulation (JVC) and no clinical observations were 
noted after treatment.  At 0.083, 0.167, 0.25, 0.33, 0.5, 0.75, 1, 2, 3 and 4 hours post-dose, rats 
were anesthetized and 0.25 mL whole blood was drawn via carotid artery cannula (CAC) into 
heparinized tubes (with EDTA) followed by complete exsanguination. After each blood draw, 
rats were injected with 0.25 mL normal saline (0.9% sodium chloride, USP) to maintain a 
constant blood volume. Plasma was immediately separated by centrifugation at 13000gr-max for 
5 minutes, and transferred to glass culture
 
tubes. Samples were frozen at -20°C until analysis.   
2.1.5.2 Sample Preparation 
Standard curves and quality control samples (n=3 for each concentration) were prepared 
in control rat plasma. For plasma samples, a 50 μL aliquot of sample was precipitated with 200 
μL of acetonitrile containing internal standard using a VWR Multi-Tube Vortexer (VWR, 
Bridgeport, NJ).  For brain samples, 50 μL of blank plasma was added to 50 μL of homogenized 
(4-fold dilution in 60/40 Isoproponal/Water) sample.  For brain standards and blanks, 50 μL of 
control rat brain homogenate was added to 50 μL of plasma.  The resulting 100 μL of sample 
was precipitated with 300 μL of acetonitrile containing internal standard using a VWR Multi-
Tube Vortexer.  All samples were then centrifuged at 3000 rpm for 10 minutes with a standard 
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laboratory centrifuge (Eppendorf, Westbury, NY).  The supernatant was collected in a clean 96-
well collection plate and 5 μL was injected onto the HPLC for LC/MS/MS analysis. 
2.1.5.3 6-MPR and 6-MP Bioanalysis 
LC/MS/MS analysis was performed for 6-MPR and 6-MP using a high-performance 
liquid chromatography system with CTC PAL autosampler (Leap Technologies, Carrboro, NC) 
interfaced to an API 4000 LC/MS/MS quadrupole tandem mass spectrometer (Applied 
Biosystems/ MDS Sciex Inc., Ontario, Canada). 6-MPR, 6-MP and the internal standard (CP-
628374) were separated on a Waters Atlantsi HILIC column 
 (50 x 2.1 mm, 5μm) by isocratic 
elution.
35
 Mobile phase A consisted of 95% Acetonitrile and 5% 200 mM ammonium formate in 
water, pH 3.0.  Mobile phase B, which was used as a 0.5 minute wash step, consisted of 50% 
Acetonitrile, 45% HPLC Grade Water, and 5% 200 mM ammonium formate in water, pH 3.0.  A 
flow rate of 650 μL/min was used.  
The mass spectrometer was operated in negative ion ESI mode for the detection of                 
6-MPR and the Internal Standard (CP-628374).  Multiple reaction monitoring was performed 
with the transitions m/z 283.2  151.1 for 6-MPR, m/z 685.3  366.1 for CP-628374 (internal 
standard).  The mass spectrometer was operated in positive ESI mode for the detection of 6-MPR 
and the Internal Standard (CP-628374).  Multiple reaction monitoring was performed with the 
transitions m/z 153.1  119 for 6-MP, m/z 687.3   319.7 for CP-628374 (internal standard).  
All raw data was processed using Analyst Software v.1.4.2 (Applied Biosystems/ MDS Sciex 
Inc., Ontario, Canada).  The lower limits of quantification (LLOQ) for 6-MPR and 6-MP were 
2.44 and 9.76 ng/mL, respectively. The upper limit of quantification (ULOQ) was 1250 ng/mL. 
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2.1.5.4 Pharmacokinetic Analysis 
Mean concentrations of 6-MPR and 6-MP were used in the analysis. Paired student's t-
test was used to determine statistical significance and was assessed at the 5% level (p < 0.05). 
Pharmacokinetic analysis was performed using standard noncompartmental methods as 
implemented in Watson Kinetica™ Version 5.0 Software (Thermo Scientific, Waltham, MA). 
Linear-up/log-down method of estimation was used to calculate area under the concentration-
time curve (AUC). Total body clearance (CL) was calculated as dose divided by AUC and 
adjusted for body surface area .The steady state volume of distribution (Vdss) was calculated as 
the ratio of CL to the slope of the terminal log-linear phase – the elimination rate constant (ke). 
The terminal half-life (t½) was calculated as ln2 divided by ke. Initial concentration (Co) and 
percentage of AUC extrapolated (AUC%extra) are obtained by extrapolating the first and last 
concentrations, respectively.  
2.1.6 In Vitro Experiment – 6-MPR metabolism in rat liver homogenate  
2.1.6.1  Liver homogenate preparation 
Liver homogenates were prepared using livers obtained from male Sprague-Dawley rats 
(200-250 grams). The livers obtained were either used fresh or stored at -70°C until use. The 
liver was perfused with saline, removed and rinsed in phosphate buffer (pH 7.4). Liver, weighing 
roughly 10 grams, was homogenized in 5mL of 0.01M Tris-HCL buffer (pH 8.0), containing 
1mM EDTA for 5 minutes in a potter glass homogenizer equipped with a Teflon pestle. The 
homogenate was rapidly heated to 55°C for 5 minutes and then cooled quickly to below 10°C in 
an ice bath. The animals used in this study were those that were sacrificed as part of other 
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experiments approved by the Pfizer Global Research and Development Animal Care and Use 
Committee and complied with the NIH Guide for the Care and Use of Laboratory Animals.  
2.1.6.2 Incubation of liver homogenate with 6-MPR-AuNPs 
200 μL of 6-MPR (with and without AuNPs), 6-MPR-AuNPs (with and without AuNPs), 
and 6-MPR-AuNPs plus 6-MPR were each incubated in 3mL of liver homogenate at 37°C with 
continuous shaking (60 RPM). 6-MPR was also added to the liver homogenate in the presence of 
5mM allopurinol (xanthine oxidase inhibitor). To ensure that 6-MPR did not decompose in the 
assay buffer (Tris-HCL containing EDTA), a solution of 6-MPR in the buffer was tested under 
conditions similar to homogenate assay. As a control, a portion of rat liver homogenate was pre-
treated with citrate-stabilized AuNPs for 24 hours prior to incubation with 6-MPR. The 
concentration of 6-MPR or AuNPs in the test formulations was maintained at 0.9mM.  
100 μL aliquots were collected at 5, 30, 60, 120 and 180 minutes after incubation, and 
each aliquot was added to 75 μL of ice-cold 50% (w/v) trichloroacetic acid to quench any 
reaction.  The mixture was centrifuged for 10 min at 1500g and filtered through Acrodisc LC13 
0.2 μm filters (Gelman Sciences). The resulting samples were kept at 0 - 4°C until analyzed.  
Samples collected were assayed for 6-MPR and 6-MP by LC-MS/MS as described below.  
2.1.7 In Vitro Experiment – 6-MPR metabolism in HepG2 cell culture 
2.1.7.1 Inverted colloidal crystal hydrogel scaffold preparation 
Inverted colloidal crystal (ICC) hydrogel scaffolds were prepared following a previously 
described method.
36  
Briefly, cylindrical shape colloidal crystal templates (diameter 6 mm, height 
1 mm) were constructed with size-controlled glass beads (diameter 173 ±17µm).  
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Acrylamide hydrogel precursor solution composed of 30% w/w acrylamide, 5% w/w N,N-
methylenebisacrylamide and 0.1% v/v N,N,N,N tetramethylethylenediamine in nitrogen purged 
deionized water was infiltrated into colloidal crystals via centrifugation and radically 
polymerized upon addition of 1% w/w potassium peroxide solution. Once polymerization was 
completed, the hydrogel matrix exterior of the colloidal crystals was trimmed down and the glass 
beads were dissolved in 5% w/w hydrogen fluoride solution. The leftover 3-D hydrogel matrix 
retained an inverted structure of colloidal crystal template. ICC hydrogel scaffolds were 
subsequently washed with acidic solution (pH 2), deionized water and phosphate-buffered saline 
solution. Finally, ICC hydrogel scaffolds were freeze-dried and preserved in a -70ºC freezer until 
used.  
2.1.7.2 HepG2 spheroid cell culture 
Rehydrated ICC hydrogel scaffolds were sterilized in 70% ethanol for 15min under UV 
light and subsequently washed with PBS solution three times. HepG2 (HB-8065, ATCC) human 
hepatocarcinoma cells were expanded with William‘s E Medium supplemented with 10% fetal 
bovine serum and 1% penicillin-streptomycin in a 37ºC incubator with 5% carbon dioxide.
 
The 
cells were harvested from flasks using 2.5% Trypsin-ethylenediaminetetraacetic aicd (EDTA) 
solution, once 70-80% confluence was reached. Final cell concentration was adjusted to 25x10
6
 
cells/ml. 20µl of cell suspension, containing approximately 0.5x10
6
 cells was dropped on top of a 
slightly dehydrated ICC hydrogel scaffold.  After 20-30 min, the cell-loaded scaffolds were 
transferred to a 48-well plate containing 1.5ml of culture medium. HepG2 cells formed 
homogenous spherical clusters within the scaffold after 5 days.
 37,38    
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2.1.7.3 Microscope imaging 
Morphology of colloidal crystals, ICC hydrogel scaffolds and HepG2 spheroids were 
characterized under scanning electron microscope (FEI Nova Nanolab). Cell spheroids were 
fixed with 2.5% glutaldehyde and then serially dehydrated with 50, 70, 90, 95 and 100% ethanol 
solutions.  Before imaging, completely dried samples were coated with Au (Desktop2, Venton 
Vacuume Inc.). Diffusion of a cell tracker dye molecule between 2-D flat and 3-D spheroid 
culture was characterized under laser scanning confocal microscope (Leica SP2). HepG2 cells in 
both 2-D and 3-D cultures were incubated in 5µM carboxyfluorescein diacetate succinmidyl 
ester (CFDA-SE, Invitrogen) solution for 20min and subsequently washed three times with PBS 
solution.  Fluorescent signal was detected using 490-550nm emission bands with a 457nm 
excitation laser.  
2.1.7.4 Treatment of HepG2 spheroid culture with 6-MPR-AuNPs 
Homogenous hepatic spheroids formed within ICC scaffolds placed in 48-well and 24-
well plates were used as a 3-D and 2-D culture formats, respectively. In order to directly 
compare drug effects, total cell mass and culture volume were maintained as 0.5x10
6
 cells and 
1.5mL, respectively. Half the volume of media was changed daily for 5 days. On day 6, 2-D and 
3-D culture media were each replaced with 1.5mL of 0.25mg/mL 6-MPR, 0.25mg/mL 6-MPR 
conjugated AuNPs, or 1:1 v/v of 0.25mg/mL 6-MPR and 0.25mg/mL allopurinol. The 6-MPR 
and 6-MPR-AuNPs used in these experiments were identical to those used in the animal studies. 
200µl of supernatant was collected at 15, 30, 45, 60, 90, 120 and 240 minutes after incubation 
for analysis. Triplicate samples were pulled per time-point. Collected samples were stored at -
70°C freezer until analyzed. After sample collection, the cultures were exposed to a Trypsin-
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EDTA solution to detach cells either for 2-D culture or 3-D aggregation.  Total DNA contents in 
3-D and 2-D culture were measured using PicoGreen dsDNA quantification kit (Invitrogen), 
which was used to normalize the results. Cell-scaffolds were mechanically destroyed using 
forceps and sonicated to make a cell lysate solution. Supernatant was collected from the three 
test groups for analysis.  
We calculated the area under the curve (AUC) of 6-MPR concentration-time curve to 
determine the effect of AuNPs on 6-MPR in the HepG2 cell culture.  Statistical analyses were 
done by using SPSS for Windows (version 16.0; SPSS, Inc., Chicago, Illinois, USA). A P-value 
<0.05 was considered statistically significant. 
2.1.8 Sample Preparation 
 Standard curves were prepared in control cell culture media. 50 μL aliquot of sample 
was precipitated with 200 μL of acetonitrile containing internal standard using a VWR Multi-
Tube Vortexer (VWR, Bridgeport, NJ).  All samples were then centrifuged at 3000 rpm for 10 
minutes with a standard laboratory centrifuge (Eppendorf, Westbury, NY).  The supernatant was 
collected in a clean 96-well collection plate and 5 μL was injected onto the HPLC for 
LC/MS/MS analysis. 
2.1.9 6-MPR and 6-MP Analysis 
LC/MS/MS analysis was performed for 6-MPR and 6-MP using a HPLC system with 
CTC PAL autosampler (Leap Technologies, Carrboro, NC) interfaced to an API 4000 
LC/MS/MS quadrupole tandem mass spectrometer (Applied Biosystems/MDS Sciex Inc., 
Ontario, Canada).  6-MPR, 6-MP and the internal standard (CP-628374) were separated on a 
Waters Atlantsi HILIC column
  (50 x 2.1 mm, 5μm) by isocratic elution. The reader is advised to 
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refer to previous sections on the bioanalysis of brain, CSF and plasma samples for the detailed 
analytical method used to analyze 6-MPR and 6-MP samples. All data were processed using 
Analyst Software v.1.4.2 (Applied Biosystems/ MDS Sciex Inc., Ontario, Canada).  The lower 
limits of quantification (LLOQ) for 6-MPR and 6-MP were 2.44 and 9.76 ng/mL, respectively. 
The upper limit of quantification (ULOQ) was 425ug/mL. 
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2.2 RESULTS AND DISCUSSION 
 
2.2.1 Gold Nanoparticles  
 
Drug-loaded AuNPs were synthesized taking advantage of the ability of 6-MPR to bind 
to gold via the thiol end of the molecule. Reduction of Au(3+) by borohydride in the presence of 
6-MPR (see Method) yielded 5.12 nm ± 0.3 (Figures 2-2-3a and 2-2-3b). The electrokinetic 
potential (ξ) and surface area of 6-MPR-AuNPs were +7.2 mV and 30.59µm2 respectively. The 
concentration of bound 6-MPR in the resulting NP dispersion was 0.25 mg/mL. Similarly, the 
concentration of 6-MPR and allopurinol solutions used in the experiments was each 0.25mg/mL. 
 
 
 
Figure 2-2-3. Gold nanoparticle characterization: (A) Transmission electron micrograph 
of  6-MPR-AuNPs with mean size of ca.5.12 nm ± 0.30 (mean ± S.D.). (B) 6-MPR-AuNPs  
particle size histogram.   
 
 
A 
 
B 
 
   50 nm         Diameter (nm) 
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2.2.2 Pharmacokinetics 
 
Male Sprague-Dawley (SD) rats received 5 mg/kg intravenous injections of 6-MPR-
AuNPs and 6-MPR solution, as control. The resulting mean plasma concentration-time profiles 
are shown in Figure 2-2-4, and the pharmacokinetic parameters are provided in Table 2-1. As 
expected, markedly different pharmacokinetic profiles were observed for the two groups. The 
rats treated with the control formulation experienced a precipitous drop in systemic 6-MPR and 
6-MP levels compared to the rats treated with 6-MPR-AuNPs.  
The 6-MP plasma concentration for rats administered 6-MPR alone was well below the 
9.76 ng/mL lower limit of quantification. The initial drug concentration (C0) and area under the 
curve (AUC) of 6-MPR for rats treated with 6-MPR-AuNPs were 11,440±3860 and 3,695 ±315 
ng/mL•h, respectively. This is compared to 50.75±1.45 and 12.45±1.25 ng/mL•h for rats given 6-
MPR alone. This represents a 297-fold increase in 6-MPR exposure compared to rats treated 
with 6-MPR. Correspondingly, the nanoparticles increased the half-life of 6-MPR from 
13.8±5.94 to 44.16±1.98 minutes.  
             The steady-state volume of distribution (Vdss) of 6-MPR decreased from 25.55±13.05 
L/kg (control group) to 0.554±0.10 L/kg for rats dosed with 6-MPR-AuNPs. This decrease in 
volume of distribution could be due to the localization of nanoparticles in the systemic 
circulation and reduced tissue binding, compared to the unconjugated 6-MPR.  
The intrinsic clearance of 6-MPR and 6-MP were also significantly lower after receiving 
6-MPR-AuNPs, averaging 22.45±1.95 and 68.7±3.01 mL/min/kg, respectively. The clearance of 
the control group was 6,190±810 mL/min/kg. Since the glomerular filtration rate alone cannot 
totally account for the observed clearance and no active carrier-mediated secretory process has 
been suggested in the urinary excretion of thiopurines,
39-41  
extensive extrarenal clearance can be 
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inferred. Rather, these results are consistent with the dramatic decrease of total clearance (276-
fold), which has a more profound effect on half-life than volume of distribution. That is because 
the volume of distribution is dependent on free plasma drug, whereas both free and bound drug 
are available for clearance. The high clearance observed in this study for free drug is consistent 
with widely-reported hepatic metabolism of 6-MPR in vivo.
42   
We hypothesize that conjugation of 6-MPR to AuNPs may have inhibited the metabolic 
inactivation of 6-MPR by XO.  Alternatively, one may suggest that 6-MPR-AuNPs could avoid 
metabolism of 6-MPR by preventing diffusion of 6-MPR into intracellular spaces of liver cells 
where XO-catalyzed metabolism occurs. In order to test these hypotheses, we carried out 
metabolic studies using different in-vitro models such as rat liver homogenate, spheroid 3D cell 
culture of hepatocytes in specially designed scaffolds, and 2D liver cell cultures. Systematic 
study of 6-MPR in the free and NP-conjugated form, at various levels of cellular complexity 
allowed us to comprehensively test these hypotheses.   
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Figure 2-2-4. Mean concentration-time profiles of 6-MPR and 6-MP in Sprague Dawley  
rats following intravenous administration (5 mg/kg 6-MPR) of 5 nm 6-MPR-AuNPs or 
unconjugated 6-MPR. Each point and bar represents the mean ± S.D. (n = 3). 
 
 
 
Table 2-1. Pharmacokinetic parameters of 6-MPR and 6-MP in Sprague Dawley rats  
after intravenous administration (5 mg/kg 6-MPR) of 5nm 6-MPR-AuNPs or 
unconjugated 6-MPR. Data represents the mean ± S.D. (n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        *Value below 9.76ng/mL  
                   
 
Parameters 
  6-MPR-AuNP group       6-MPR group 
     Mean ±SD                   Mean ±SD 
          (n=3)                            (n=3) 
AUC (ng/mL•h) 
6-MPR                      3695  ± 315                      12.45 ± 1.25   
6-MP                  1195  ± 55                        BLQ*  
% AUC Extrap (%) 
6-MPR        0.937 ± 0.184                   8.68 ± 2.82                         
6-MP         2.05 ± 0.1                         BLQ  
Co (ng/mL) 
6-MPR        11440 ± 3860                   50.75 ± 1.45                        
6-MP         4410 ± 2170                     BLQ* 
t1/2 (hours) 
6-MPR        0.736 ± 0.033                   0.23 ± 0.10                         
6-MP         0.466 ± 0.091                   BLQ*  
CL (mL/min/kg) 
6-MPR        22.45 ± 1.95                     6190 ± 810                         
6-MP         68.70 ± 3.10                     BLQ*  
Vdss (mL/kg) 
6-MPR        554    ± 102                      25550 ± 13050                        
6-MP         2035  ± 75                        BLQ* 
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2.2.3 Metabolism of 6-MPR-AuNPs in rat liver homogenate 
 
Free 6-MPR, 6-MPR-AuNPs and other combinations of NPs and 6-MPR were incubated 
in rat liver homogenate. Samples were collected for up to 180 min after incubation and analyzed 
for 6-MPR. Statistical significance (p-value <0.01) was achieved. The results showed that the 
concentration of 6-MPR declined precipitously within the initial 5 minutes of incubation, and fell 
below analytical detection limits within 120 minutes of incubation (Figure 2-2-5). On the 
contrary, 6-MPR-AuNPs increased the amount of 6-MPR by about 30-fold in the first 60 
minutes. We added citrate-stabilized AuNPs to the homogenate containing 6-MPR-AuNPs and 
found no change in 6-MPR concentration. Moreover, when 6-MPR was added to samples pre-
incubated with  6-MPR-AuNPs, we observed an almost exact increase in the amount of 6-MPR 
as was added to homogenate. Interestingly, when 6-MPR was not conjugated to NPs and instead 
admixed with free 6-MPR, a fair amount of inhibitory effect was still observed. This could be 
because some of the 6-MPR gets adsorbed to the surface of the NPs effectively forming 6-MPR-
AuNPs. 
             To confirm the effect of XO and the effects of NPs on XO, we investigated the 
metabolism of 6-MPR in the homogenate after incubation with allopurinol (a XO inhibitor). The 
result shows that the effect of  6-MPR-AuNPs is comparable to that of allopurinol. Moreover,  
when rat liver homogenate was pre-treated with stabilized AuNPs for 24 hours prior to 
incubation with 6-MPR,  metabolism of 6-MPR occurred as previously noted. This eliminates 
the possibility for XO poisoning or deactivation by the AuNPs.  Similarly, albeit to a lesser 
extent, we observe rapid decline in 6-MPR after incubation with mixture of 6-MPR and AuNP, 
further confirming that AuNPs do not poison XO. Chemical decomposition of 6-MPR in buffer 
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was also evaluated and the drug was found to be stable. These results, including the fact that 
adding excess 6-MPR or AuNPs did not change the 6-MPR in liver homogenate, confirm that 6-
MPR-AuNPs directly inhibit XO and thereby prolong the half-life of 6-MPR.  
By AuNPs inhibiting the oxidation of 6-MPR to 6TU, 6-MPR can be converted to the 
active metabolite 6-thioguanine (6TGN). The presence of 6TGN as was confirmed in rat plasma 
samples provides further evidence that AuNPs play an important role in preventing the 
metabolism 6-MPR. This also confirms that the biological properties of 6-MPR is conserved 
after conjugation to AuNPs and after subsequent interaction with XO. Podsiadlo and Kotov 
previously demonstrated that AuNPs do not diminish 6-MPR activity, instead they enhance the 
antitumor properties of 6-MPR.
32
 Based on the results here, we propose that the AuNPs does in 
fact prevent metabolic degradation of 6-MPR from occurring by inhibiting XO, while still 
allowing the phosphorylation necessary for the cytotoxic effects of 6-MPR to take place at the 
riboside end. 
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Figure 2-2-5. Metabolic stability of 6-MPR in rat liver homogenate monitored post-incubation. 
6-MPR concentration (Mean ± S.D; n=6) of six test groups at different time points, after 
incubation in liver homogenates obtained from male Sprague-Dawley rats.  
 
2.2.4 Characterization of HepG2 spheroid culture 
 
Standardized and functional in vitro tissue culture model is important for achieving 
faithful and reproducible drug testing results.
43 
The pore size distribution of ICC hydrogel 
scaffolds (D=173 ±17µm) made with a cell-repulsive synthetic hydrogel matrix effectively 
induces multicellular aggregate formation of HepG2 cells having narrow size distribution 
(D=99.9 ±14µm). This is important for controlled and reproducible testing results (Figure 2-2-
6.). Established 3-D hepatic spheroid culture replicates tissue-like morphology and functions, as 
well as physiological processes such as diffusional delivery of nutrients and oxygen.  
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In order to characterize delivery of drug or small molecules, we expose 2-D flat and 3-D 
spheroid culture to a cell tracker dye molecule and then used confocal microscopy to determine 
their distribution. As shown in Figure 2-2-7, morphological differences between 2-D flat and 3-D 
spheroid culture result in significantly different staining profiles. For example, in 2-D culture, all 
cells are homogenously stained. On the other hand, in 3-D culture, only cells located on the 
surface are fully stained and the inner cells are exposed to less dye molecules due to diffusion via 
cellular layer. This feature closely resembles molecular delivery in tissue cells. It is highly 
conceivable that the drug molecules or nanoparticles undergo similar transport processes in the 
body. Such diffusion limitation in 3-D spheroid culture is one of the reasons for reduced drug 
effect compared to 2-D culture.  
  
 
  
 
Figure 2-2-6. SEM images of ICC 
hydrogel scaffolds and 3D hepatic 
spheroid culture models. (A) 
Colloidal crystal templates 
prepared with 180-220 µm 
microspheres (Left) and inverted 
structure made of polyacrylamide 
hydrogel matrix (Right). The 
structure of a tightly packed 
narrow size distribution of 
microspheres was transferred to 
3D homogenous spherical pore 
arrays. (B) HepG2 spheroid 
formation after 5 days of culture 
(Left) and HepG2 spheroid under 
high magnification (Right). Cell 
repulsive nature of 
polyacrylamide hydrogel matrix 
rapidly induces   cellular 
aggregation. 
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Figure 2-2-7. Comparison of 
cell tracker dye molecule 
diffusion between 2-D and 3-D 
HepG2 cell cultures under 
confocal microscope. Left 
panel is a fluorescent image 
and right panel is a fluorescent-
transmission overlay image. 
(A) In conventional 2D flat 
culture, entire cells were 
homogenously stained with a 
dye molecule. (B) In 3D 
spheroid culture, only exterior 
regional cells were stained with 
a dye molecule due to the 
diffusion limit.   
 
 
2.2.5 Metabolism of 6-MPR-AuNPs in HepG2 spheroid assay  
 
Using standardized liver spheroid culture model we studied the potential effect of AuNPs 
on the metabolism of 6-MPR by liver XO. We measured the concentration of 6-MPR and 6-MP 
in the  2-D and 3-D HepG2 cell culture media over the course of 4 hours after incubation with 6-
MPR, a mixture of allopurinol and 6-MPR, and AuNP-6-MPR. The results show that in the 
presence of gold nanoparticles, metabolism of 6-MPR and 6-MP was significantly reduced 
(Figure 2-2-8 and Table 2-2). The 6-MP and 6-MPR concentrations in the cell cultures were 
respectively 3 and 4-fold lower than reference, when cells were exposed to free drug alone. 
However, when cells were incubated with 6-MPR-AuNPS, the concentrations of 6-MP and           
6-MPR remained unchanged. Similarly, cell cultures incubated with a mixture of 6-MPR and 
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allopurinol showed little or no change in the initial concentrations of 6-MPR and 6-MP. In this 
case the 6-MPR-AuNPs performed comparably to the mixture of 6-MPR and allopurinol.  
              When cells were treated with AuNPs, the 6-MPR concentration was comparable to cells 
treated with a mixture of 6-MPR and allopurinol. These results are consistent with previous in 
vivo observations. However, analysis of cell lysate revealed that 2D cells treated with 6-MPR-
AuNPs contained the same amount of 6-MPR as cells incubated with free 6-MPR (Table 2-3). 
Interestingly, 3D cell lysate for the 6-MPR-AuNPs group had lower amounts of 6-MPR 
compared to other treatment groups. One possible explanation for this is that the extraction of            
6-MPR-AuNPs from the cell-scaffolds matrix was incomplete, rendering the lysate assay sub-
potent. This is the so-called matrix effect and presents distinct challenges to molecular analysis 
of biological matrices.
44-46
   
           Though the effect of AuNPs on 6-MPR was similar in 2D and 3D liver culture models, the 
normalized AUCs of 6-MP and 6-MPR in 3D culture were significantly lower than in 2D culture 
(roughly two orders of magnitude). This reflects the large number of cells present in the 3D 
scaffold (701,158 ±57991 per scaffold), compared to the same culture volume of 2D well plate 
(10,832 ±1745 cells per well). Further unlike 2D cell culture models, 3D hepatic cells produced 
concentration profiles with elimination processes that are characteristic of in vivo models. In the 
3D culture, 6-MP and 6-MPR concentrations seem to decline exponentially with time.  
Though in some cases they can provide useful information, in vitro 2D cell cultures often 
do not accurately predict complex physiological processes such as would be encountered in drug 
metabolism. Cellular processes are strongly dependent on 3D organization and limit the ability of 
2D cell models to reproduce in vivo responses.
47  
3D culture restores tissue-like morphology and 
phenotypes that, in turn, significantly improve prediction of drug response compared to 
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conventional 2D flat culture. The use of liver spheroid culture model to evaluate hepatic 
clearance of drugs has significant implications on the development of drugs. 
             Several human liver in vitro assays have been developed in the past few decades. These, 
include supersomes, microsomes, cytosol, S9 fraction, cell lines, transgenic cell lines, primary 
hepatocytes, liver slices, and perfused liver. However, in vitro cell culture models have been 
primarily based on two-dimensional (2-D) monolayer of cells, which despite providing valuable 
information do not accurately predict tissue morphology and functions. This may be because key 
physiological processes are absent from cell assays.  
These limitations have prompted the development of three-dimensional (3-D) cell culture 
models. Compared to the 2-D culture of cell monolayers, 3-D models can provide a cellular 
microenvironment that more closely mimics the conditions observed in native tissues. 
48,49                
This is critical for drug testing since environmental cues can have profound effects on the 
properties, behaviors, and functions of cells. These, in turn, affect cellular responses to drugs. 
Factors such as matrix composition, cell type, cell health, cell seeding densities, and time of 
culture can influence the success of 3-D cultures.  
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Figure 2-2-8. Normalized drug concentration-time profiles of three formulations of 6-MPR in 2-D and 3-D HepG2 
spheroid culture. (A) 6-MPR in 2-D culture, (B) 6-MP in 2-D culture, (C) 6-MPR in 3-D culture, (D) 6-MP in 3-D 
culture. Mean ± S.D. (n = 6).   
A 
 
B 
 
C 
 
D 
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Table 2-2. Normalized area under concentration-time curve of 6-MPR and 6-MP in 2D and 3D 
HepG2 culture 
 
 
Formulation 
 
      6-MPR (ng/mL/cell•h) 
         Mean ±SD (n=6)                          
            6-MP (ng/mL/cell•h)                                              
Mean ±SD (n=6) 
     2-D culture        3-D culture    2D culture                3D culture 
      6-MPR 
 
10.132 ±0.9      0.172 ±0.06 
 
 16.837 ±1.1       0.286 ±0.1 
        6-MPR+ allopurinol 
 
66.012 ±2.1  0.747 ±0.1 
 
 61.959 ±1.5      0.700 ±0.2 
      6-MPR-AuNP   45.716 ±1.4  0.744 ±0.3  42.316 ±1.3      0.712 ±0.3 
         
 
 
 
Table 2-3: Normalized mean concentrations of 6-MPR and 6-MP in 2D and 3D HepG2 culture lysate 
 
   Formulation 
 
       6-MPR (ng/mL/cell) 
         Mean ±SD (n=6)                         
                6-MP (ng/mL/cell) 
               Mean ±SD (n=6)                          
     2-D culture       3-D culture            2-D culture                     3-D culture 
     6-MPR 
 
0.071 ±0.03     0.045 ±0.01 
 
0.087 ±0.02      0.046 ±0.02 
       6-MPR + allopurinol  
 
0.075 ±0.09     0.015 ±0.01 
 
0.078 ±0.03      0.016 ±0.01 
    6-MPR-AuNP    0.072 ±0.06     0.001 ±0.02   0.080 ±0.02      0.002 ±0.002 
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2.3 CONCLUSIONS 
 
 The BBB penetration of drug molecules alone does not guarantee optimum brain 
delivery. Therefore optimizing drug pharmacokinetics is critical to the development of drug 
therapies and particularly CNS therapies. Here, we used in vitro and in vivo pharmacokinetics 
studies to demonstrate that AuNP carriers can dramatically increase the plasma half-life of 6-
MPR, by directly inhibiting liver xanthine oxidase (XO) activity. To our knowledge, this 
phenomenon has not been previously observed for other nanoscale carriers of 6-MPR.   
These results have several important clinical implications. 6-mercaptopurine is a well 
established antineoplastic agent.  Optimizing 6-MPR therapy to maintain high systemic exposure 
is critical to effective clinical management of inflammatory diseases and malignancies, including 
potentially brain tumors.  In addition, lower dose requirements and increase drug therapeutic 
index will result.   
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CHAPTER 3 
BRAIN PENETRATION, DISTRIBUTION AND PHARMACOKINETICS                                         
OF 6-MERCAPTOPURINE RIBOSIDE CONJUGATED GOLD NANOPARTICLES 
 
3.0 INTRODUCTION 
 
Each year, approximately 14,000 people are stricken with brain cancer. Despite major 
advances in diagnostics and treatment options, the ability to treat the most aggressive and 
common form of malignant brain tumor, glioblastoma multiforme (GBM), has not improved 
since 1980.
1 
 GBM is the most frequent primary brain tumor type in adults, comprising about a quarter 
of all primary brain tumors diagnosed in the United States. The one-year survival rate for invasive 
central nervous system (CNS) cancers was 57.9 percent in 2002, and survival for GBM in 
particular was even lower.
2  
Even with aggressive multimodal therapy consisting of radiotherapy, 
chemotherapy, and surgical excision, the median survival is only 12–17 months.3  
One reason for this is that the majority of the potent systemic chemotherapeutic agents 
are excluded from the CNS by the Blood-Brain Barrier (BBB) and Blood-Cerebrospinal Fluid 
(BCSF) Barriers.
4
 The BBB is composed of a tightly sealed layer of endothelial cells and 
astrocytes and plays a critical role in protecting the brain from toxic and infectious agents, while 
allowing the intake of nutrients, oxygen and essential molecules. Highly complex and tightly 
regulated, the BBB screens the biochemical, physicochemical and structural features of solutes in 
its periphery, thus affording barrier selectivity in the passage of molecules into the brain 
parenchyma.  
The ability to treat neurological diseases is therefore limited by the efficient function of 
BBB and BCSF barrier. In addition, BBB efflux proteins such as P-glycoprotein and ABCG2 act 
like gate keepers to keep the chemotherapeutics out of CNS. A few compounds classified as 
nitrosoureas (including carmustine and lomustine) or alkylating agents (e.g. temozolomide) have 
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partial ability to cross the BBB and have been used clinically in the recent past.
5 
 However, 
systemic delivery of these agents appears to offer modest benefit as a supplement to 
radiotherapy. 
6,7  
In effect, the BBB and BCSF act as a bottleneck to the development of effective 
brain delivery systems.  
The failure of conventional drug therapy for treating glioma has motivated extensive 
research into innovative strategies to deliver chemotherapeutics across the BBB. Over the past 
two decades, a variety of approaches to deliver CNS-excluded drugs through the BBB have been 
attempted by various research groups with mixed results. These have included hyperosmolar 
disruption of the BBB tight junctions and direct delivery of therapeutics into the brain by 
intracerebral injection into cerebral parenchyma or cerebral ventricles.
8,9  
Both approaches are 
invasive, and have severe adverse effects with a prominent disadvantage of repeated 
administration of therapeutic agents.  
With better understanding of the BBB, several targeting strategies are being tested for 
brain delivery, with some success.
10  
Receptor-mediated delivery of drugs conjugated to known 
BBB carriers such as transferrin, apotransferrin and other ligands have been tested.
11 
Liposome 
and nanoparticles with similar targeting moieties have also been evaluated. However despite the 
fact that some of these approaches have achieved increased drug delivery into the brain, the 
therapeutic efficacy decreases either due to chemical modifications or a poor drug penetration 
thus limiting their usefulness.
12 
 The ability to cross the BBB would enable a wider range of 
agents such as paclitaxel, doxorubicin, immunotoxins, and even gene therapy vectors to be 
evaluated for brain cancer treatment. 
In order to overcome the poor permeability of the BBB as well as poor pharmaceutic 
properties of currently marketed chemotherapeutic agents, we have put forward a novel drug 
delivery strategy which involves the conjugation of 6-MPR to gold nanoparticles (6-MPR-
AuNPs). The proposed research utilizes whole-body section fluorescence imaging (WBSFI) 
technique, as well as detailed brain, CSF and plasma PK analyses to study the brain uptake and 
CNS distribution of 6-MPR-AuNPs following intravenous injection of rats.  
In the recent past, gold nanoparticles have attracted considerable attention for medical 
research.  This is because AuNPs are chemically stable, biocompatible, easy to functionalize for 
specific targeting, and have special plasmonic properties.
13− 17  
The intravenous lethal dose 
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(LD50) of 1.9 nm AuNPs was found to be minimal (3.2 g/kg) in acute toxicity studies conducted 
in mice.
18 
As a contrast agent, AuNPs provide a suitable tool for diagnostics and imaging.
 19− 21  
Moreover, the luminescence of gold and its electron density allow its visualization and 
characterization by numerous techniques such as spectrophotometry, fluorescence microscopy, 
computer tomography (CT), and transmission electron microscopy (TEM). Previous experiments 
which reported the entry of citrate stabilized gold nanoparticles (AuNPs) into the brain after 
intravenous administration showed that gold nanoparticles with a diameter cut-off of 15 nm or 50 
nm could pass through the BBB efficiently.
 18,22  
Although several studies are available on the use 
of gold nanoparticles for diagnostic and therapeutic applications, detailed analysis of the 
pharmacokinetics and brain distribution of drugs conjugated to gold nanoparticles is nonexistent 
or incomplete. Further investigation of the distribution and kinetics of drug conjugated AuNPs is 
warranted, and will help shed light on the safety and efficacy of nanotherapeutics in general.  
Additionally, recent development of better fluorescent tags as well as advances in image 
computing, have sparked new interest in the use of optical imaging as a medical diagnostic. 
WBSFI is increasingly gaining popularity as a qualitative tool used in non-clinical drug research.
 
23,24   
WBSFI is similar to QWBA, but fluorescence intensity is measured instead of radioactivity. 
In WBSFI, flourophores are used to visualize disposition of tagged drug molecules in 
whole body section of small animals. Compared to other imaging methods, WBSFI is safe, fast, 
inexpensive, requires little sample preparation while maintaining high sensitivity. It was not the 
aim of the present publication to review in detail the performances of WBSFI and QWBA. 
Rather we focus on the new possibilities offered by 6MPR-AuNPs combined with WBSFI.  
Purine antimetabolites, 6-mercaptopurine (6MP) and 6-mercaptopurine riboside (6MPR) 
are antineoplastic agents widely used in the clinical treatment of Acute Lymphoblastic Leukemia 
(ALL), meningeal leukemia, other malignancies, and inflammatory bowel disease (IBD).
25 
 Short 
plasma half-life due to rapid liver metabolism has limited their clinical use. Furthermore, only 
limited published information is available on the brain distribution of 6-MPR and other purine 
analogs. Available studies suggest that 6-MPR is only marginally distributed in the CNS.
 25
   
The mechanism of action of purine antimetabolites involves the conversion of 
mercaptopurine into cytotoxic 6-thioguanine nucleotide (6-TGN), which is then incorporated 
into the DNA or RNA of nucleated cells by hypoxanthine-guanine phosphoribosyl transferase 
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(HGPRT) instead of the naturally occurring purine bases (Figure 3-1-1).
26  
These events 
ultimately lead to cell death and is thought to be the source of the antineoplastic effects of 
mercaptopurines. Conventional therapies with mercaptopurines are however susceptible to 
extensive enzymatic inactivation by hepatic xanthine oxidase, resulting in short plasma half-life 
and large variability in cytotoxic efficacy.
27, 28  
The pathway involves conversion of 
mercaptopurine to 6-thiouric acid, and thiopurine methyltansferase catalysis of S-methylation to 
6-methylmercaptopurine.
29  
The importance of optimizing 6-MP therapy to maintain high 
systemic exposure is therefore critical to effective clinical management of Acute Lymphoblastic 
Leukemia (ALL). 
In this article we present compelling animal data to show that 6-MPR-AuNPs 
significantly increased the concentrations of 6-MPR and 6-MP in brain, CSF and plasma. The 
AuNPs decreased the clearance and thereby increased the plasma half-life of 6-MPR. Finally, 
TEM and whole-body imaging analysis was used to confirm the brain uptake of 6-MPR-AuNPs.  
Considering the anatomical complexity of the blood-brain-CSF barriers and the inherent 
difficulty in delivering drugs to the brain, the significance of finding AuNPs in brain and 
cerebrospinal fluid cannot be overstated.  
To our knowledge, this is the first time a pharmacological agent has been directly 
delivered to brain parenchymal cells using gold nanoparticles as vectors. We are also unaware of 
reports of transvascular delivery of the chemotherapeutics agent (6-MPR) across the blood-brain 
using AuNPs, combined with the potential for other novel drug delivery applications. 
Furthermore, to-date, there have been no reported cases of the successful use of whole-body 
fluorescence to investigate tissue distribution of nanoparticles in lieu of whole body 
autoradioluminography as we have demonstrated in this article. Finally, drug design strategies 
for treating brain malignancies have often emerged from empirical studies with retrospective 
pharmacologic explanations, rather than prospective trials involving rational design as we have 
done here. 
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Figure 3-1-1. Schematic of the metabolism of 6-mercaptoputine (6MP) and 6-mercaptopurine 
riboside (6MPR). 6MPN, 6-mercaptopurine nucleotides; 6TGN, 6-thioguanine nucleotides; 
6MMP, 6-methylmercaptopurine; 6MMPR, 6-methylmercaptopurine riboside; 6MMPN, 6-
methylmercaptopurine nucleotides; 6TU, 6-thiouric acid; TPMT, thiopurine methyltransferase, 
HPRT, hypoxanthine phosphoribosyltransferase; XO, xanthine oxidase.  
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3.1 METHODS 
 
3.1.1 Materials 
 
6-Mercaptopurine riboside, 6-Mercaptopurine, trisodium citrate dihydrate, 
tetrachloroauric (III) acid trihydrate, sodium borohydride, L-cysteine and fluorescein 
isothiocyanate isomer I (FITC) were purchased from Sigma-Aldrich and utilized without further 
purification. Ultrapure water (Barnstead) with 18.2 MΩ-cm was used for all experiments.  
3.1.2 6-MPR-AuNPs and FITC/6-MPR-AuNPs Synthesis 
 
Citrate stabilized gold nanoparticles were freshly prepared and used immediately for the 
synthesis of 6-MPR-AuNPs and FITC/6-MPR-AuNPs (Figure 3-1-2). Gold sol was prepared by 
sodium borohydride reduction of tetrachloroauric (III) acid solutions following previously 
reported methods, 
30−32 42-44 
with some modifications. Briefly, 5 mL of 1 w/w% tetrachloroauric 
(III) acid solution was diluted in 50 mL of ultrapure water and stirred for one minute. Next 2.5 
mL of 3.4mM sodium citrate was added and the resulting solution was stirred for one minute.            
5 mL of 0.075 wt% sodium borohydride was then added to the gold solution.  
6-MPR-AuNPs were labeled with FITC via an L-cysteine linker.  50 mL aqueous 
solution containing a 2:1 molar ratio of 6-MPR and Cysteine were added to the reaction vessel 
containing gold sol 30s after sodium borohydride. The resulting solution was dialyzed against 
ultrapure water for 3 days and was further purified by ultracentrifugation at 45000 rpm (190000 
gr max) to a final volume of 20mL. To the resulting dispersion, a 1mL solution containing 
0.58umol of FITC was added and after adjusting the pH to 8, the mixture is allowed to stir 
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overnight in darkness at room temperature. Next, the solution is placed in a dialysis bag and 
allowed to purify against ultrapure water for approximately one week or until no more FITC was 
eluting. The resulting NP solution was stored in a refrigerator and protected from ambient light, 
until further use.  
 
 
 
 
 
Figure 3-1-2. Flow diagram for the chemical synthesis of 6-MPR-AuNP (route A) and FITC/6-
MPR-AuNPs (route B) 
 
 
 
 
 
 
 
 
 
A B 
  71  
 
3.1.3 Nanoparticle Characterization  
 
3.1.3.1 TEM Imaging 
Transmission electron microscopy (FEI Tecnai, G2 Sphera) imaging was performed on 
FITC/6-MPR-AuNP and 6MPR-AuNP solutions at 100,000 times magnification. Mean surface 
area and diameter of the particles were then determined using Image-Pro Plus software (Media 
Cybernetics). To prepare samples for TEM, 2-5 μL aliquots of the sample were placed onto 
carbon-coated formvar covered support grids and air-dried overnight in a protective 
environment. Representative images from samples at 100,000x were used to acquire sufficient 
(greater than 100) nanoparticle objects for image analysis. Images were processed to optimize 
particle segmentation. Statistics and frequency histograms were generated. The zeta potential of 
6MPR-AuNP was measured using Zetasizer Nano ZS, Malvern Instruments. Finally, High 
Pressure Liquid Chromatography (Agilent HPLC System) was used to determine the 
concentration of 6MPR immobilized on the surface of AuNPs by digesting the gold colloids with 
potassium cyanide.  
3.1.3.2 AFM Imaging 
Atomic force microscopy (AFM) imaging was performed using a Nanoscope III (Digital 
Instruments/ Veeco, Santa Barbara, CA) instrument. AFM images were obtained in the tapping 
mode with standard Si/N tips. Calibration at the nanoscale, operating in Tapping Mode (TM) was 
performed using standard samples. Images were recorded by working in low voltage mode. In 
this configuration the set point was about 1 nN, and the scan rate 2 Hz. Glass slides were cleaned 
by immersion in a freshly prepared solution consisting of 30% H2O2 and 96% H2SO4 in 1:2 ratio. 
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The glass substrates were then washed with milli-Q water and dried in a stream of high-purity 
nitrogen. Subsequently, the glass surface was treated with 0.3M (3-mercaptopropyl)-
trimethoxysilane solution in chloroform for 3 minutes at room temperature. The slides were 
finally rinsed with copious chloroform and milli-Q water and dried with nitrogen gas. Gold 
colloids were deposited on silanized glass slides by spin coating. Spin speed and time were 
adjusted to ensure high density of homogeneously distributed single colloidal particles over the 
glass substrate. 
3.1.4 Animal Studies  
Male Sprague-Dawley rats weighing on average 250-300 grams with surgically 
implanted vascular cannulas in the carotid artery and jugular vein were purchased from Charles 
River Laboratories (Willmington, MA). Rats were housed one per cage in an American Animal 
Association Laboratory Animal Care accredited facility and maintained under standard 
conditions of temperature (22 ± 2 ºC), relative humidity (50%) and light and dark cycles (12 
hours /12 hours). Rats were allowed to acclimate
 
to their environment for one week. Rats had 
access to food and water ad libitum throughout the study. Experiments were conducted according 
to procedures approved by the Pfizer Global Research and Development Animal Care and Use 
Committee and complied with the NIH Guide for the Care and Use of Laboratory Animals.  
3.1.4.1 Whole-Body Imaging Experiment 
Rat whole-body fluorescence imaging studies were conducted following standard 
procedure for whole-body autoluminography. The experimental setup (Figure 3-1-3) consisted of 
a cryomicrotome, the imaging system, a robotic positioner and the computer control system.                 
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A custom application program has been developed which controls the cryostat, the robotic 
positioner, the illuminators and the camera for a fully automated sectioning and imaging session. 
A total of six rats were used in the study. Three rats (treatment groups 1-3) were intravenously 
administered FITC/6-MPR-AuNP (5 mg/kg FITC), and the remaining three rats received either 
saline, FITC or FITC + 6-MPR-AuNP as control. The saline group was included to control for 
both the drug administration and temporary restraints used. All rats were injected via the tail vein 
using 20-gauge gavage-dosing needle affixed to a 3cc disposable syringe.  
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Rats euthanized post-dosing
Euthanized animal frozen in -75oC 
chamber of dry ice and hexane for 10mins
Frozen whole-body specimens embed unto 
microtome stage using 3% CMC
25μm sagittal sections are acquired and lifted
onto 810 scotch tape at –18oC 
Sections are scanned with a Typhoon 9210 Molecular 
Dynamics Imager to acquire digitized images
Images are analyzed with a processing and visualization software that 
includes suppression algorithm to correct for background interference.
Rats injected with Saline, 
FITC, FITC/6MPR-AuNPs 
 
 
 
 
Rats were then euthanatized by CO2 asphyxiation 30 minutes following dose 
administration. Immediately following euthanasia, each rat was prepared by immersion into a 
freezing chamber (-75
o
C) containing dry ice and hexanes for 10 minutes. Next the frozen whole-
body specimen was embedded onto a microtome stage using 3% carboxy-methylcellulose. 25μm 
sagittal sections were captured on type 810 Scotch tape at –18oC. Sections were then freeze-dried 
at –18oC for a minimum of 72 hours. The cryosections were scanned with a Typhoon 9210 
Figure 3-1-3. Procedure flow diagram of rat whole-body fluorescence experiment. 
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Molecular Dynamics Phosphor Imager to acquire computerized images optimized for detecting 
FITC. Tissue sections were spotted with matrix solution to generate a linear concentration–
response relationship over a 1000-fold concentration range of FITC. Photographic registration 
was obtained by averaging fluorescence measured at different sectioning levels and from 
replicate cryosections obtained from the same sectioning level. The acquired images were 
analyzed with a processing and visualization system. Background scans acquired prior to dosing 
were fed into a suppression algorithm to correct for background interference.  
 
3.1.4.2 Brain, CSF, Plasma Distribution Study  
 
SD rats (three per timepoint) received a slow fixed bolus injection of 6MPR-AuNPs (5 
mg/kg active) via JVC, with no clinical observations. 6MPR solution was administered as a 
control. At 0.083, 0.25, 0.5 and 0.75 hours post-injection, rats were euthanized by carbon 
dioxide, and plasma, cerebral spinal fluid and brain were collected for analysis. Whole blood was 
collected via carotid artery cannula (CAC) into heparinized tubes (with EDTA) followed by 
complete exsanguination. After each blood draw, rats were injected with 0.25 mL normal saline 
(0.9% sodium chloride, USP) to maintain a constant blood volume. Plasma was immediately 
separated by centrifugation at13000 gr-max for 5 minutes, and transferred to glass culture
 
tubes. 
Samples were stored frozen at -20°C until analysis. CSF was collected via puncture of the 
cisterna magna using a 23 gauge needle attached to polyethylene tubing (internal diameter of 50 
mm) and syringe. Whole brains were harvested, rinsed in phosphate buffered saline and weighed. 
Brain samples were homogenized in 60:40 isopropanol: water immediatley after 
harvesting. All samples were immediately frozen on dry ice until analysis. Sagittal sections of rat 
brain were obtained 15 minutes post-injection for TEM imaging. The brain was removed 
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immediately from the skull, fixed in chilled 2.5% glutaraldehyde solution for 2 hours and then 
embedded into epoxy resin. The tissues were allowed to equilibrate to room temperature for 
approximately one hour before sectioning. Ultra-thin (60-80nm) sagittal sections were cut using 
an ultramicrotome with a diamond knife. The specimen was placed onto carbon-coated formvar 
covered support grids. Three adjacent brain slices from the same animal were collected. After 
being stained with uranyl acetate and lead citrate, the specimens were observed on a TEM. 
 
3.1.4.3 Sample Preparation 
Standard curves and quality control samples (n=3 for each concentration) were prepared 
in control rat plasma. For plasma samples, a 50 μL aliquot of sample was precipitated with 200 
μL of acetonitrile containing internal standard using a VWR Multi-Tube Vortexer (VWR, 
Bridgeport, NJ).  For brain samples, 50 μL of blank plasma was added to 50 μL of homogenized 
(4-fold dilution in 60/40 Isoproponal/Water) sample.  For brain standards and blanks, 50 μL of 
control rat brain homogenate was added to 50 μL of plasma.  The resulting 100 μL of sample 
was precipitated with 300 μL of acetonitrile containing internal standard using a VWR Multi-
Tube Vortexer.  All samples were then centrifuged at 3000 rpm for 10 minutes with a standard 
laboratory centrifuge (Eppendorf, Westbury, NY).  The supernatant was collected in a clean 96-
well collection plate and 5 μL was injected onto the HPLC for LC/MS/MS analysis. 
 
3.1.4.4 6-MPR and 6-MP Bioanalysis 
LC/MS/MS analysis was performed for 6MPR and 6MP using a high-performance liquid 
chromatography system with CTC PAL autosampler (Leap Technologies, Carrboro, NC) 
interfaced to an API 4000 LC/MS/MS quadrupole tandem mass spectrometer (Applied 
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Biosystems/ MDS Sciex Inc., Ontario, Canada). 6MPR, 6MP and the internal standard (CP-
628374) were separated on a Waters Atlantsi HILIC column
33 (50 x 2.1 mm, 5μm) by isocratic 
elution.  Mobile phase A consisted of 95% Acetonitrile and 5% 200 mM ammonium formate in 
water, pH 3.0.  Mobile phase B, which was used as a 0.5 minute wash step, consisted of 50% 
Acetonitrile, 45% HPLC Grade Water, and 5% 200 mM ammonium formate in water, pH 3.0.  A 
flow rate of 650 μL/min was used.  The mass spectrometer was operated in negative ion ESI 
mode for the detection of 6MPR and the Internal Standard (CP-628374).  Multiple reaction 
monitoring was performed with the transitions m/z 283.2  151.1 for 6MPR, m/z 685.3  
366.1 for CP-628374 (internal standard).  The mass spectrometer was operated in positive ESI 
mode for the detection of 6MPR and the Internal Standard (CP-628374).  Multiple reaction 
monitoring was performed with the transitions m/z 153.1  119 for 6MP, m/z 687.3   319.7 
for CP-628374 (internal standard).  All raw data was processed using Analyst Software v.1.4.2 
(Applied Biosystems/ MDS Sciex Inc., Ontario, Canada).  The lower limits of quantification 
(LLOQ) for 6MPR and 6MP were 2.44 and 9.76 ng/mL, respectively. The upper limit of 
quantification (ULOQ) was 1250 ng/mL. 
3.1.4.5 Pharmacokinetic Analysis 
Mean concentrations of 6MPR and 6MP were used in the analysis. Paired student's t-test 
was used to determine statistical significance and was assessed at the 5% level (p < 0.05). 
Pharmacokinetic analysis was performed using standard noncompartmental methods as 
implemented in Watson Kinetica™ Version 5.0 Software (Thermo Scientific, Waltham, MA). 
Linear-up/log-down method of estimation was used to calculate area under the concentration-
time curve (AUC). Total body clearance (CL) was calculated as dose divided by AUC and 
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adjusted for body surface area .The steady state volume of distribution (Vdss) was calculated as 
the ratio of CL to the slope of the terminal log-linear phase – the elimination rate constant (ke). 
The terminal half-life (t½) was calculated as ln2 divided by ke. Initial concentration (Co) is 
obtained by extrapolating the first measured concentrations.  
3.1.4.6 Brain, CSF, and Plasma TEM Imaging 
TEM (FEI Tecnai, G2 Sphera) imaging was performed on samples of brain, cerebral 
spinal fluid (CSF) and plasma. 2µL aliquots of CSF, plasma, brain homogenate, or rat brain 
sagittal samples were placed onto carbon-coated formvar covered support grids and air-dried 
overnight in a protective environment. Due to variation in the viscosity of CSF, plasma and brain 
homogenate samples, as well as issues with electron beam penetration, additional aliquots of 
samples diluted with nuclease-free water were examined in order to facilitate visualization in the 
electron microscope. Imaging was performed on sample preparations at a 10,000 – 200,000x 
magnifications with accelerating voltages between 50 and 120kV. 
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3.2 RESULTS AND DISCUSSION 
 
In preliminary experiments conducted in our laboratory, 5nm 6-MPR-AuNPs labeled 
with fluorescein isothiocyanate (FITC) was intravenously administered into male Sprague-
Dawley (SD) rats. Imaging analyses of rat sagittal sections revealed strong fluorescence 
responses in several tissues, including cerebrum, cerebellum and spinal cord. Based on these 
results, we further conducted detailed brain distribution and pharmacokinetics studies using the 5 
nm 6MPR-AuNPs.   
3.2.1 Nanoparticles 
 
3.2.1.1 Transmission electron microscopy  
Transmission electron microscopy (TEM) imaging analysis of the FITC/6-MPR-AuNPs 
revealed mean particle size and surface area of ca.5.57 nm and 30.22 µm
2
, respectively. The 
electrokinetic potential of FITC-6-MPR-AuNPs was +8.1 mV. Similarly the particle size of         
6-MPR-AuNPs was 5.12 nm, surface area was 30.59 µm
2 
and the zeta potential was +7.4 mV. In 
contrast to FITC/6-MPR-AuNPs, 6-MPR-AuNPs had a slightly less positive surface charge. 
TEM micrographs are shown in Figure 3-2-1a and Figure 3-2-1d. Histogram (Figure 3-2-1c and 
Figure 3-2-1f) based on TEM analysis of over 125 particles revealed a monodisperse particle-
size distribution. Finally, the concentration of 6-MPR on the surface of the AuNPs was 
determined to be 0.25 mg/mL.  
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3.2.1.2 Atomic force microscopy  
Tapping mode (TM)-AFM was carried out on the glass substrates. However, before TM-
AFM analysis, samples were first tested by CM-AFM. Except for the presence of occasional            
2 nm deep holes, the surface was quite flat, exhibiting a RMS roughness ranging between 0.3 to 
0.5 nm over a 500 x 500 nm
2
 area. Single colloids appear stably bound to the MPTMS glass 
substrate, and display homogeneous lateral and vertical dimension, with no evidence of 
aggregates. Micrographs of colloids are shown in Figure 3-2-1b and Figure 3-2-1e.  
The particles had mean value of 5.3 nm with a standard deviation of 0.53 nm. The 
minimum and maximum measured heights are 4.5 and 7.2 nm, respectively. The 5.5 nm mean 
value of nanoparticle height, which provides an estimate of colloid diameter, is in agreement 
with values obtained from TEM and by the TM-AFM imaging characterization. This clearly 
indicates the absence of height artifacts. The lateral size (evaluated as the full width at half 
maximum (FWHM) of the nanoparticle cross section profile) is monodispersed and significantly 
broadened because of the well known tip convolution effect. 
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Figure 3-2-1 (a) Transmission electron micrograph of FITC/6-MPR-AuNPs  (b) TM-AFM 
topographic image of of FITC/ 6-MPR-AuNPs deposited on MPTMS treated glass  (c) Particle 
size histogram of FITC/6-MPR-AuNPs based on TEM analysis of 100 different nanoparticles 
(d) Transmission electron micrograph of 6-MPR-AuNPs  (e) TM-AFM topographic image of of 
6-MPR-AuNPs deposited on MPTMS treated glass  (f) Particle size histogram of 6-MPR-
AuNPs based on TEM analysis of 100 different nanoparticles. 
 
3.2.1.3 Whole-Body Fluorescence Imaging  
The biodistribution of 5 nm FITC/6-MPR-AuNPs following intravenous administration  
to Sprague-Dawley (SD) rats was investigated using whole-body cryosectioning combined with 
fluoroluminography (Figure 3-1-3). Across treatment groups analyzed (N=17 organs per group), 
widespread organ distribution was detected in several tissues (Figure 3-2-2) including bone 
marrow, cerebellum, cerebrum, myocardium, skeletal muscle, spinal cord, testis, salivary gland 
and liver, within 30 minutes of intravenous administration.  
a 
 
b c 
 
e 
 
f 
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Compared to the control group, the fluorescence intensity for rats injected with FITC/           
6-MPR-AuNPs was highest in cerebrum, cerebellum, and cerebrospinal fluid followed by 
kidney, liver, spleen, lungs, bone marrow and brown adipose tissue (Table 3-1 and Figure 3-2-3).  
Image analysis suggests that substantial CNS uptake of FITC/6MPR-AuNPs (treatment groups 
1-3) occurred. Fluorescence intensity in the brain and the inner regions are high, suggesting 
penetration of the blood-brain barrier by gold nanoparticles. On the other hand, rats given saline, 
FITC, or mixture of FITC and 6-MPR-AuNPs as a control, exhibited no or poor overall spatial 
distribution with no signs of uptake into brain or CSF. This suggests poor penetration of the 
blood-brain-CSF barriers by FITC, which has been previously reported.
 34  
Extensive fluorescence in liver, kidney, bladder and lungs of rats administered 
FITC/6MPR-AuNP reflects the pivotal role of these organs in the clearance of nanoparticles after 
intravenous injection. Urinalysis was not performed, but the urine voided during the first 45 
minutes after injection was clearly green to yellow in color, confirming urinary excretion of the 
test substance. The accumulation in bone marrow is especially interesting, since it is the main 
site of cytotoxic action of 6MPR in leukemia. One way ANOVA followed by Student-Newman-
Keuls post-hoc analysis showed statistically significant difference between FITC/6-MPR-AuNPs 
compared to the vehicle treated group (p<0.05). 
Though some untreated tissues exhibited autofluorescence, whole blood produced 
fluorescence well above background levels. This observation was expected as hemoglobin is 
known to quench fluorescence of fluorophores.
 35  
To reduce the effect of autofluorescence, 
images were processed by fitting background-corrected fluorescence intensity. Using subtraction 
processing algorithm, interference from tissue components was substantially reduced.  However, 
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in the interpretation of fluorescence images, one must bear in mind that the autofluorescence of 
tissues especially in the intestines, liver and bile cannot be completely eliminated.  
The present paper describes a novel application of whole-body section fluorescence 
imaging (WBSFI) combined with FITC-6MPR-AuNPs for fast evaluation of systemic and 
central distribution of a drug candidate. Compared to other techniques, fluorescence imaging is 
inexpensive, less laborious and presents minimal safety concerns. WBSFI also has the advantage 
of having most organs available on the same section, thus permitting comparison of the test 
article in organs.  
A major improvement of the presented approach is the use of a novel read-out 
technology, which overcomes the conventional time-consuming and potentially hazardous nature 
of autoradiographic film. Due to the high sensitivity and the rapidity of fluoroluminography, the 
protocol has the potential to be used for general screening of centrally active compounds, as 
exemplified here using 6MPR-AuNPs. However, the use of fluorescent labels for bioimaging 
presents certain challenges, including photobleaching, light scattering, autofluorescence by 
tissues, and unintended release of fluorescent tag. Also densitometric analysis such as WBSFI is 
quasi-quantitative.  
Despite these limitations, WBSFI has proven to be a powerful tool for understanding 
drug disposition in early drug research. Finally, as mentioned previously, a significant finding of 
this study is the increase in fluorescence in the CNS after injection with FITC/6MPR-AuNPs 
compared to the control. The mere possibility that FITC/6MPR-AuNPs penetrated the CNS 
within 30 minutes of injection presents exciting possibilities and warrants further investigation. 
In light of these findings, detailed brain distribution and pharmacokinetic studies were also 
undertaken and the results are presented below. 
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Figure 3-2-2. Whole-body fluorograms of rats administered (a) saline solution (b) 5 mg/kg FITC 
(c) 5 mg/kg (FITC + 6-MPR-AuNPs) (d-f) 5 mg/kg FITC/6-MPR-AuNPs. Images represent average 
fluorescence intensity measured from replicate cryosections of Sprague-Dawley rats sacrificed 30 
minutes after intravenous injection.  The intrinsic autofluorescence measured in the control rats are 
subtracted to get the fluorescence intensity map.  Intensity of color corresponds to increasing 
fluorescence (red<orange<yellow < green< blue< black).  
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Tissue\Matrix 
 
Control: FITC+6MPR-AuNPs 
                MDC/mm
2
           
 
 Treatment group A               
     MDC/mm
2
 
      
Treatment group B 
            MDC/mm
2
    
 
 Treatment group C 
       MDC/mm
2
     
    
 
      
Adrenal Gland  45238312 ±114   1569566 ± 170    1669696 ± 124   1506502 ± 113  
Blood      ----     ----      ----     ----  
Bone Marrow    5084673 ± 201 44770476 ± 189  51841127 ± 169 52061329 ± 194  
Brown Adipose  26536103 ± 214   1173443 ± 217    1473486 ± 224   1575091 ± 202  
Cerebellum      491023 ± 229 24788491 ± 211  26964974 ± 246 24244603 ± 251  
Cerebrum      702038 ± 671 23705402 ± 401  25939686 ± 241 26126285 ± 356  
Gastric 
Contents 
   4826859 ± 167   5693628 ± 219    6137381 ± 312   5366603 ± 210  
Intestinal Contents    6964151 ± 193   7286975 ± 146    6467393 ± 162   6819425 ± 211  
Kidney      894972 ± 123 12343706 ± 176  14952639 ± 182 11980845 ± 213  
Liver    6842549 ± 183   8461729 ± 146    7815999 ± 143   8526023 ± 312  
Lung      802003 ± 132   5110253 ± 146    4786501 ± 162   5450291 ± 124  
Myocardium  14671000 ± 189     404344 ± 156      449367 ± 172     490341 ± 231  
Skeletal 
muscle 
 18940032 ± 102   1613146 ± 121    2167256 ± 181   1534071 ± 123  
Spinal Cord      442786 ± 157    24297416 ± 181  20523301 ± 146 22778001 ± 231  
Spleen    1956425 ± 144   9018464 ± 152    9534925 ± 183   8898953 ± 164  
Testis  15626887 ± 119   7993181 ± 122    8290970 ± 128   8876797 ± 102  
Thymus    6108133 ± 124     548771 ± 131      520040 ± 153     610119 ± 136            
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Figure 3-2-3. Treatment to control fluorescence concentration ratios (Mean ± SEM) in 
select tissues of Sprague Dawley rats. Each bar represents n=10 replicates per group.  
Table 3-1. Fluorescence response of tissues in whole-body sections of Sprague Dawley rats following 
administration of vehicle control and Cys-FITC/6-MPR-AuNP 
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3.2.1.4 Brain, CSF, Plasma Distribution       
Mean brain, CSF and plasma concentrations are presented in Tables 3-2 and 3-3. Also the 
pharmacokinetic profiles of 6-MPR-AuNPs and unconjugated 6-MPR (control) are presented in 
Figure 3-2-4. The calculated pharmacokinetic parameters are summarized in Table 3-4. The 
difference in CSF and plasma 6-MPR concentrations for the control group was not statistically 
significant (p>0.05) and lower than levels found in the brain. Similarly for rats treated with 6-
MPR-AuNPs, the difference between brain and plasma 6-MP was not statistically significant 
(p>0.05). For this group, the AUC of plasma 6-MPR was higher than the corresponding plasma 
6-MP. The opposite was observed when unconjugated 6-MPR was administered. Overall these 
results revealed that brain, CSF and plasma levels of 6-MPR and 6-MP were higher in rats 
treated with AuNPs compared to the control group. 
 Specifically, the 6-MPR AUC0.083-0.75 h of brain, CSF and plasma were respectively 3, 2.3 
and 145 fold higher in the rats administered with 6-MPR-AuNPs compared to rats treated with 
6MPR alone. Similarly, the 6-MP AUC for rats dosed with 6-MPR-AuNPs was higher relative to 
the control group. The slow conversion of 6MPR to 6-MP in rats treated with 6-MPR-AuNPs led 
to reduced 6-MP penetration into brain. This in itself is not a limitation since 6-MPR (unlike 6-
MP) is itself a biologically active moiety. In general, the AuNPs provided approximately 6-times 
less conversion of 6-MPR to 6-MP in plasma. This is not unexpected and consistent with the 
high 6-MPR clearance (6076±412 mL/min/kg) in the control group, compared to the clearance 
(41.88±3.24 mL/min/kg) in rats that were given 6MPR-AuNPs. Similarly, the 6-MP clearance 
for the control group was 3149.51±354 mL/min/kg compared to 136.23±16.1 mL/min/kg for 6-
MPR-AuNPs treated rats. These results are not unremarkable considering that the surface area of 
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brain capillaries is one-tenth that of the liver and with one-fifth the blood transit time of liver. 
Furthermore, the dose of AuNPs administered in this study was less than 0.2% of the LD50 of 
1.9 nm AuNPs.
18 
Despite rapid elimination of 6-MPR and 6-MP, equilibration between plasma and CSF 
compartments after the administration of 6-MPR is achieved within one-half hour, albeit at low 
drug concentrations. Interestingly for the control group, the CSF concentration of 6-MP was 
much higher than the total plasma concentration of 6-MP. Since in general only the unbound 
fraction of drug in plasma can diffuse across the blood-brain barrier, the results suggest the 
possibility for plasma protein-binding. The free drug concentration available for brain 
penetration is influenced by processes, such as tissue binding in blood and brain, metabolism in 
the liver and brain, and active influx and efflux. Certainly on the basis of the physicochemical 
properties of 6-MP, passage into the CNS is to be expected.
36
  The results provide additional 
evidence to substantiate the potential clinical benefits of 6-MP for treating leukemic 
meningitis.
37  
The presence of 6MP in CSF after intravenous administration was first reported by 
Hamilton and Elion.
38  
However, data on its disposition to CSF has not been available until now. 
Given the extensiveness of thiopurine metabolism, conventional assessment of CNS drug 
delivery based on brain-plasma and CSF-plasma partition coefficients provided little useful 
information. Rapid conversion of 6-MPR to metabolites as well as highly exaggerated 
concentrations of 6-MPR in plasma (for rats given 6-MPR-AuNPs) prevented equilibrium from 
being reached, which is a prerequisite for performing such analyses. This study further highlights 
several important considerations when interpreting CNS data. Many investigators report brain-
plasma and CSF-plasma ratios. However, because drug entry into CNS may be delayed and the 
half-life of drug in CNS could differ significantly from that of blood, the drug brain-plasma or 
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CSF-plasma ratio could lead to erroneous conclusions. Exaggerated drug pharmacokinetics, 
typical of drug carrier systems, as well as the timing of specimen collection must be properly 
considered. Therefore a more appropriate parameter to measure in CNS studies is the absolute 
concentration of free drug relative to the therapeutic concentration.
39  
In general, tools 
traditionally used to assess the ADME properties of NCEs have not been able to adequately 
describe nanotechnology drug-delivery systems.
 40 
  
Increases in 6MPR and 6MP concentrations in the brain and CSF of rats immediately 
after the administration of 5 nm 6MPR-AuNPs is significant because of the potential implication 
on the delivery of important CNS drugs. Much like drugs which successfully cross the BBB, the 
brain uptake of 6-MPR-AuNPs raises the possibility that these particles have unique 
physicochemical properties that facilitate BBB penetration. 
 
 
Table 3-2. 6-MPR and 6-MP mean (n = 3) plasma concentrations following intravenous injection 
of 5nm 6MPR-AuNPs (5 mg/kg active) to Sprague-Dawley rats. 
 
 
Subject 
 
 
Hours 
Brain (ng/g) CSF (ng/mL) Plasma (ng/mL) 
6MPR 6MP 6MPR 6MP 6MPR 6MP 
Rat 7,   8,  9 0.083 499.5 ± 121 3870 ±1024 217.5 ±67 632 ±114 4760 ±874 2375  ±324 
Rat 10,11,12 0.25 332 ± 91 1800 ±412   69.95 ±13   226.5 ±85   3710 ±684   996.5 ±144 
Rat 13,14,15 0.50 131 ±34 505 ±132   13.49 ±87   104.5 ±41   2735 ±304   613.5 ±94 
Rat 16,17,18 0.75 123.7 ±74 342.5±87     8.45 ±2   95.85 ±24   1081 ±128   418 ±124 
    
 
Table 3-3. 6-MPR and 6-MP mean (n = 3) plasma concentrations following intravenous injection 
of 6-MPR (5 mg/kg) to Sprague-Dawley rats. 
 
 
Subject 
 
 
Hours 
Brain (ng/g) CSF (ng/mL) Plasma (ng/mL) 
6MPR 6MP 6MPR 6MP 6MPR 6MP 
Rat 19,20,21 0.083 149  ±95 1950 ±758 47.4  ±24 249 ±87 47.7 ±14  168 ±80 
Rat 22,23,24 0.25 105  ±83 593  ±169   34.4  ±14   157 ±86   24.8 ±8   24.4 ±11 
Rat 25,26,27 0.50   47  ±31 222  ±91   15  ±9*   110 ±64*   12.8 ±6   26.8 ±13 
Rat 28,29,30 0.75   49  ±39 191  ±89   8.87 ±6    99 ±47   10.9 ±5   5.15 ±2 
* Sample deactivated due to blood contamination; values are interpolated based on noncompartmental analysis.  
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 Figure 3-2-4. Mean brain, CSF and plasma concentration-time profiles of (a) 6-MPR (b) 6-MP in Sprague Dawley 
rats following single intravenous administration (5 mg/kg 6-MPR) of 5 nm 6MPR-AuNPs or unconjugated 6-MPR. 
Each point and bar represents the mean (n = 3) ± S.D. 
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*Value below 6.76ng/mL 
 ―– ―: Estimation of brain and CSF PK parameters is outside the scope of current experiments. Modeling 
experiments will be needed to determine these values 
 
 
3.2.1.5 Brain, CSF, and Plasma TEM Imaging  
TEM imaging was performed on brain, CSF and plasma samples to determine whether or 
not AuNPs were present in these tissues. Representative images of the dosing solution and 
biological samples are presented with accompanying scale bar markers (Figure 3-2-5a - 3-2-5h). 
Large numbers of particles were observed in brain, CSF and plasma samples, confirming the 
presence of AuNPs in the CNS. AuNPs can be seen in brain matrix at 5, 15, 30 and 45 minutes 
after injection of 6-MPR-AuNPs. In all cases, though to a lesser extent in plasma, the 
hydrodynamic size of the nanoparticles increased relative to the dosing solution.  
Proteins present in blood, CSF and brain matrixes may have adsorbed onto the surfaces 
of AuNPs and altered the effective hydrodynamic size.
41  
The extent of this effect is dependent 
on protein concentration and other thermodynamic factors.
 42 
 It was also observed that the 
 
  Parameters 
 
   6MPR 6-MPR-AuNPs 
Brain  
   (ng/g) 
CSF      
(ng/mL•h) 
       Plasma  
            (ng/mL•h) 
  Brain  
  (ng/g) 
CSF      
   (ng/mL•h) 
           Plasma  
            (ng/mL•h) 
     
AUC(6MPR) 0.083-0.75 h                     52 ± 9     16 ± 4         14 ± 7  159 ± 9   37 ± 7          1990 ± 23 
  Co (ng/mL)                              192 ± 35     65 ± 15       55 ± 8 422 ± 17     248 ± 12  T6        955 ± 15 
  T1/2 (hours)                 –          –    0.19 ± 0.10                                         –            –        0.71 ± 0.18                    
  CL (mL/min/kg)                 –          –   6076 ± 810                                                –      –        42 ± 19                      
  Vdss (mL/kg)                 –          –   7184 ± 305                                        –            –        87 ± 13                       
    
  AUC(6MP) 0.083-0.75 h        366 ± 18      93 ± 7        27 ± 4          868 ± 11      138 ± 16             612 ± 14 
  Co (ng/mL)   2151 ± 25    278 ± 27      178 ± 25 4599 ± 15            697 ± 12     2664 ± 75                         
  T1/2 (hours)                  –           –       BLQ*                  –                    –         0.38 ± 0.05                    
  CL (mL/min/kg)                  –           –       BLQ*                  –                    –        136 ± 31                      
  Vdss (mL/kg)                  –           –       BLQ*    
Table 3-4. Pharmacokinetic parameters of 6-MP and 6-MPR in brain, CSF and plasma of rats 
following intravenous administration (5 mg/kg 6-MPR) of 6MPR-AuNPs or 6-MPR. Each 
value represents the mean (n = 3) ± S.D.  
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number of particles in brain significantly decreased within forty-five minutes, indicating lack of 
persistence of the AuNPs in the CNS. Translocation of nanoparticle via the lymphatic system 
and microglia scavenger cells of the CNS has been previously reported.
43 
 
Ultra-thin sections of rat brain were examined by TEM to confirm that 6-MPR-AuNPs 
indeed penetrated intact BBB and were distributed into cerebral parenchyma. 6-MPR-AuNPs 
were not only found inside the cytoplasm of vascular endothelial cells and the foot processes of 
astrocytes, but more importantly were also found inside the cylindraxile of neurons which are not 
attached to cerebral vessels (Figure 3-2-6a - 3-2-6c). The presence of 6-MPR-AuNPs inside 
neurons indicates that the nanoparticles diffused through the vascular endothelial cells and the 
astrocytes at the BBB before reaching the neurons in the cerebral parenchyma. It is worth noting 
here that the nanoparticles are diluted at least 200-fold after leaving the endothelial cells.
44 
  
The mechanism of transport of nanoparticle across the BBB has been proposed 
45
 to 
involve one or a combination of the following events: (1) transcytosis of vascular endothelial 
cells, (2) opening of tight junctions due to nanoparticle disruption of BBB, solubilization of 
endothelial cell membrane, and (3) diffusion due to a high concentration gradient across the 
endothelial cell layer due to retention of the nanoparticles in the brain capillaries. In this study, 
TEM images (Figure 3-2-6) show that the integrity of tight junction and BBB function during 
treatment with AuNPs were maintained. Membrane morphology, intracellular endocytic vesicles 
and tight junctions all appear normal, demonstrating that AuNPs did not induce changes to the 
endothelial cell membrane. In addition, AuNPs were also found within the cytoplasm of vascular 
endothelial cells. The mechanism underlying the brain penetration by AuNPs is not fully 
understood but the authors propose that transcytosis of vascular endothelial cells is the most 
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likely mechanism involved. Additional studies on the mechanism by which nanoparticles cross 
the BBB are needed.   
 
 
 
    
    
 
Figure 3-2-5. TEM images of AuNPs observed in (a) 5 nm 6MPR-AuNP dosing solution (control) (b) plasma 
(c) CSF (d) brain – 5 minutes (e) brain – 5 minutes (adjacent grid from (d)) (f) brain – 15 minutes (g) brain – 
30 minutes (h) brain – 45 minutes, after intravenous injection of 5 nm 6MPR-AuNPs (5 mg/kg active). Images 
are representative of 20 different regions in each sample. 
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Figure 3-2-6. TEM images of brain sections sacrificed 15 minutes post-injection with 6-MPR-
AuNPs. Nanoparticles are indicated by arrow. (A) Sagital section showing endothelial cell (EC), 
basement membrane (BM), astrocytic endfeet (PA) dissociated from the basement membrane, 
perivascular space (PS) and degenerate synaptic contact (DS). Gold nanoparticles are dispersed 
in vascular, endothelial and neuronal tissue, scale bar is 0.5 µm. (B) Partial magnification of 
endothelial cell membrane, membranes junction, cerebral vascular. Gold nanoparticles shown 
inside the cytoplasm of vascular endothelial cells and the foot processes of astrocytes scale bar is 
0.3 µm. (C) Gold nanoparticles found inside the neurodendron and cylindraxile of neurons, scale 
bar is 0.3 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
  94  
 
 
 
3.3 CONCLUSIONS 
 
Collectively, the results of this study provide direct evidence that 6-MPR-AuNPs penetrated the 
BBB and diffused into cerebral parenchyma and neuronal cells. In contrast, 6-MPR was not 
found in significant amounts in the brain and CSF. The mere presence of AuNPs in brain tissues, 
minutes after intravenous administration, is a significant finding and suggests that 5nm AuNPs 
potentially provide an effective carrier for diagnosis, imaging and treatment of CNS disorders.  
In addition, enabling brain uptake of 6-MPR has the potential of advancing novel therapeutic 
uses in the treatment of brain cancer and leukemic meningitis. 
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CHAPTER 4 
GOLD NANOPARTICLES ENHANCE BRAIN PENETRATION AND CENTRAL 
DOPAMINE RECEPTOR AFFINITY 
 
4.0 INTRODUCTION 
 
Dopamine is synthesized primarily in the central nervous system (CNS) and acts as a 
neurotransmitter in the brain. Limited production also occurs in the adrenal medulla and 
nonneuronal tissues, including the pancreas and the anterior pituitary.
1
 The five subtypes of 
dopamine receptors (D1 through D5) are coexpressed at different levels in the CNS and 
peripheral tissues.
 
  
Dysfunction of dopaminergic systems is implicated in the development of defects in 
cognition, event prediction, emotion, behavior, addiction, attention deficits and 
schizophrenia.
2,3,4
 Recent findings show that the D2 and D3 receptors specifically have a diverse 
role in the pathophysiology of schizophrenia, Parkinson‘s disease and drug abuse. For instance, 
deficiency of dopamine in midbrain nigrostriatal neurons has long been recognized in the 
pathogenesis of Parkinson‘s disease 5,6, while over-activity of the limbic and cortical 
dopaminergic neurons has been implicated in schizophrenia and psychoses.
7 
 In the 
neuroendocrine axis, dysfunction of hypothalamic dopamine or its pituitary receptors leads to 
hyperprolactinemia and reproductive disturbances.
8,9,
  It is not surprising, therefore, that this 
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relatively simple molecule (Figure 4-1-1a) has been at the center of interest of basic scientists 
and clinicians alike for many years.  
Dopamine (DA) does not effectively penetrate the blood brain barrier (BBB); thus the 
brain and central nervous system are dependent upon endogenous dopamine synthesis.
 10
  L-
DOPA (Figure 4-1-1b) which is the precursor to catecholamines (neurotransmitters: dopamine, 
norepinephrine, and epinephrine) crosses the protective blood-brain barrier and since the 1960s 
has been used as the gold standard for treating Parkinson's disease.  L-dopa crosses the BBB 
transported by LAT-1 (L or Large amino acid transporter). This transporter moves amino acids 
like phenylalanine and tyrosine across the BBB.
11 
 Once inside the central nervous system,                
L-DOPA is converted into dopamine by the enzyme DOPA decarboxylase (DDC). However, 
Levodopa-induced motor fluctuations and dyskinesias constitute a significant proportion of 
adverse effects seen with sole L-DOPA administration.
12 
 Besides the central nervous system,                   
L-DOPA is also converted into dopamine from within the peripheral nervous system. 
The BBB segregates the CNS from the systemic circulation, and its main physiological 
functions include maintaining homeostasis at the brain parenchyma and protecting the brain from 
potentially harmful chemicals.
13 
 The BBB expresses a number of specific carrier-mediated 
transporters that ensure an adequate nutrient supply for the brain. 
 The BBB is primarily formed from capillary endothelial cells, which differ from the 
other tissues.
 
The brain capillary endothelial cells are very closely joined together by tight 
intercellular junctions that efficiently restrict the paracellular diffusion of drugs.
14 
 The high 
metabolic activity of brain capillary endothelial cells, as well as effective efflux systems that 
actively remove solutes from brain tissue and return them back to the bloodstream, create 
additional challenges for potential CNS drugs.
15 
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Measurement of total drug concentration within the brain is relatively simple to obtain. 
However it is difficult to correlate this information with CNS effect. Therefore, a more reliable 
parameter for establishing CNS efficacy of a therapeutic agent is the percent receptor occupancy 
(RO) of the molecular target, which can be determined from receptor binding studies.
16 
 This 
technique involves measuring the displacement (or receptor occupancy) of radioligand by the 
competing agent, coupled with liquid-scintillation counting and autoradiography. RO data 
generated this way has provided deep understanding of the involvement of neurotransmitters 
during the development of neurological disorders such as Parkinson‘s disease, schizophrenia and 
depression. 
17  
These methods however are not without limitations. Suitable radioligands for such 
a technique (i.e., with adequate specific binding) are not always available for every drug target 
18 
and may require extensive validation prior to experimentation.
19
  The radioligand may also have 
its own side effects, and being radioactive poses significant safety risks. Therefore, a more rapid 
and cost-effective imaging ligand for determining receptor occupancy would also be of immense 
value. We propose that gold nanoparticles could provide a more potent, safer and more cost-
effective alternative to current radioligands for preclinical and clinical imaging applications.  
Gold nanoparticles have attracted considerable attention in medical research because they 
are intrinsically biocompatible, have minimal toxicity, are easy to synthesize, and functionalize 
for specific targeting.
20, 21,22
  Also the luminescence of gold and high electron density allow it to 
be used as a diagnostic and imaging tool for applications, such as spectrophotometry, 
fluorescence microscopy, computer tomography (CT), and transmission electron microscopy 
(TEM).
23,24, 25
 
 
 
 
 More significantly, several studies (including our own) have reported the 
penetration of rat brain by small gold nanoparticles (AuNPs) with diameter cut-off of 50 nm, 
following intravenous administration.
26,27
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In the present study, we used receptor binding experiments to confirm the potential use of 
novel 5nm dopamine-AuNPs (Figure 4-1-1c)  to overcome the low BBB permeability of 
dopamine, while enhancing binding affinity and specificity (and therefore pharmacological 
properties) at dopaminergic receptors. Also, AuNPs may provide a more potent, safer and more 
cost-effective alternative to current radioligands. To date no studies have used dopamine-AuNPs 
to cross the BBB, and bind to dopamine target.  
 
 
 
 
 
Dopamine 
 
 
 L-
DOPA (L-3,4-
dihydroxyphenylalanine) 
 
 
 
Dopamine- AuNP 
 
Figure 4-1-1. Chemical structure of (A) Dopamine (B) L-3,4-dihydroxyphenylalanine (L-DOPA) 
(C) Schematic representation of Dopamine-AuNP. L-DOPA crosses the blood brain barrier and is 
a precursor Dopamine which does not cross the blood brain barrier. 
 
 
 
 
 
 
 
 
 
 
 
 
AuNP 
 
A C B 
  102  
 
4.1 METHODS 
 
4.1.1 Materials 
 
Hydrogen tetrachloroaurate (HAuCl4·4H2O) and sodium citrate (C6H5Na3O7·2H2O) 
were purchased from Sigma Aldridge, USA. Solvents, nitric acid (HNO3), hydrochloric acid 
(HCl) and sodium alginate were also purchased from VWR International. Deionised water (H2O) 
was purified by a Millipore system (Milli-Q). All other chemicals and solvents were of reagent 
grade. All these chemicals were used without purification. 
Fetal calf serum was obtained from PAA Laboratories. EDTA, EGTA, Tris-HCl buffer, 
NaCl, KCl, CaCl2, MgCl2, NaH2PO4, KH2PO4, D-glucose, and N-methyl-D-glucamine 
(NMDG) were obtained from Sigma-Aldrich. PBS and Hepes were obtained from Invitrogen 
Life sciences. Complete protease inhibitor cocktail tablets were obtained from Roche 
Diagnostics. Dopamine was purchased from US Pharmacopeia (Rockville, MD). 81.4 Ci/mmol 
[3H]dopamine  ([3H]DA) and 29.2 Ci/mmol GBR12783 were purchased from Amersham, Les 
Ulis, France. The reference drugs were stored in a 1mM solution at -20 °C and diluted to the 
required concentration on ice, immediately before binding assays.  All Chemicals used were of 
chemical grade.  
4.1.2 Animals  
 
All animal experiments were conducted according to procedures approved by the Pfizer 
Global Research and Development Animal Care and Use Committee and complied with the NIH 
guidelines for the Care and Use of Laboratory Animals. Male Sprague-Dawley rats were 
purchased from Charles River Laboratories (Willmington, MA). The rats were housed one per 
cage under reversed light/dark conditions using a 12 hour on/off schedule. Room temperature 
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was maintained at 21 ± 1°C with a relative humidity of 55 to 60%. Food and water were 
available ad libitum. The animals were allowed 1 week of adaptation to laboratory conditions 
before being used in experiments.   
4.1.3 Preparation of DA-AuNPs   
 
DA-AuNPs of average particle sizes 15, 50, 100 and 200 nm were synthesized using a 
method pioneered by Turkevich,
28,29
 with certain variation. The method involved reducing 
hydrogen tetrachloroaurate with sodium citrate in the presence of dopamine. Briefly, hydrogen 
tetrachloroaurate was weighed accurately (10 mg) and dissolved in 2 mL of purified water. 
Sodium citrate (400mg) weighed and dissolved in 10 mL of purified water. Hydrogen 
tetrachloroaurate solution was then added to 48 mL of the purified water which was subsequently 
added in three neck round bottom flask attached further to reflux condenser. The solution was 
heated to 100◦C and the required quantity of the sodium citrate solution (1.54×10−2 M for 15 nm, 
1.74×10
−3
M for 50 nm, 1.41×10
−3
M for 100 nm and 1.15×10
−3 
for 200 nm) was added. The color 
change of hydrogen tetrachloroaurate solution following addition of sodium citrate solution was 
noticed. The solution was heated for 10 minutes and the resulting nanoparticulate suspension was 
allowed to cool at room temperature.  
To prepare DA-AuNPs, 40 mL aqueous solution containing 12.5mg of dopamine was 
brought into contact with gold sol using a process developed in our laboratory (Figure 4-1-2). 
The two solutions were fed via peristaltic pumps at 1 mL/min and are subsequently combined in 
a single tube which is either diverted to a recirculation loop controlled by valve 3, or collected at 
the outlet (valve 4). The reaction mixture was recirculated until the measured free drug 
concentration achieves steady state. The resulting gold nanoparticles were centrifuged (40,000 
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rpm for 30min) and washed three times with millipore® water. The gold nanoparticles were 
finally suspended in 0.5% (w/v) sodium alginate solution as a suspending agent. Sodium alginate 
solution was filtered through 0.22 um millipore® filter prior to use to ensure sterility. The 5nm 
DA-AuNPs were prepared as previously described; we however substitute 6-MPR with 
dopamine.
30
 
 
 
 
Dopamine
solution
AuNP 
solution
pumppump
v1
v1: inlet valve 1
v2: inlet valve 2
v3: recirculation valve
v4: discharge valve
v2
v3
v4
DA-AuNP solution 
(Pre-purification)
 
 
Figure 4-1-2. Process for preparing AuNP with high dopamine loading on the surface. Dopamine is 
brought into repeated contact with gold solution. Feed solutions are fed via peristaltic pumps and 
recirculation loop (valve 3). The process ensures maximum contact between dopamine and nanoparticles 
solutions, thereby resulting in high dopamine loading on the surface of the AuNPs.   
  105  
 
4.1.4 Characterization of gold nanoparticles  
 
The particle size and morphology of the 5, 15, 50, 100 and 200 nm DA-AuNP solutions 
were examined by transmission electron microscope (FEI Tecnai, G2 Sphera). Imaging was 
performed at 100,000 times magnification. Mean surface area and diameter of the particles were 
then determined using Image-Pro Plus software (Media Cybernetics). To prepare samples for 
TEM,  2-5 μL aliquots of the sample were placed onto carbon-coated formvar covered support 
grids and air-dried overnight in a protective environment. Representative images from samples at 
100,000x were used to acquire sufficient (greater than 100) nanoparticle objects for image 
analysis. Images were processed to optimize particle segmentation. Statistics and frequency 
histograms were generated. The zeta potential of DA-AuNP was measured using Zetasizer Nano 
ZS, Malvern Instruments. Finally, High Pressure Liquid Chromatography (Agilent HPLC 
System) was used to determine the concentration of dopamine bound to the surface of AuNPs by 
digesting the gold colloids with potassium cyanide. Gold nanoparticles was resuspended in 
phosphate buffer (pH: 7.4, 0.154M) and the zeta potential was measured at 37
o
C. 
 
4.1.5 Human whole-cell dopamine receptor binding  
4.1.5.1 CHO-D2S cell growth and membrane preparation  
 
Chinese hamster ovary (CHO) cell line expressing the short isoform of the human D2 
dopamine receptor (CHO-D2S) cells were grown as monolayers in RPMI medium supplemented 
with 2 mM glutamine, 200 mg/mL active Geneticin, and 5% heat-inactivated fetal calf serum at 
37°C in a moist, 5% CO2 atmosphere. When confluency was reached, cells were washed with 
5mL of ice-cold buffer A (20 mM HEPES, 1mM EDTA (free acid) 1 mM EGTA, pH 7.4, with 
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KOH), removed from the flask by gentle shaking with 2mm diameter glass beads in 5 mL of 
buffer A, and homogenized with 30 strokes of a ThermoFisher Scientific Dounce homogenizer. 
The homogenate was centrifuged at 260 rpm, 3g for 10 minutes and the resulting supernatant 
centrifuged at 48000 rpm, 3g for 1 hour at 4°C. The membrane pellet was resuspended in ice-
cold buffer A to achieve a final protein concentration of 5–10 mg/mL (Bradford protein 
determination; Bio-Rad Laboratories, Inc.). Aliquots were stored at -70 °C.  
4.1.5.2 Competitive binding  
Binding experiments were performed by incubating 0.5mL aliquots of the membrane 
preparation containing 3 –15 mg of protein per tube, with [3H]-DA (81.4 Ci/mmol) in 0.2 mL of 
buffer at 37°C for 90 minutes. After incubation with the radioligand, 10
−3–103 M of dopamine 
(with or without selective dopamine inhibitor, GBR12783) and DA-AuNP (with or without 
GBR12783) were added. 250µl of AuNPs alone or mixed with dopamine, or with membrane 
suspension were used as controls. Each experiment was performed in triplicate and incubated at 
25 °C for 7 hours, by which time all binding ligands had reached equilibrium.  
Experiments were terminated by separation of bound and free radioligand by rapid 
filtration through Whatman GF/C glass fiber filters pretreated with 0.2% poly-L-lysine, using a 
BrandelM-24R cell harvester followed with four washes of 3 mL of ice-cold phosphate-buffered 
saline (140 mM NaCl, 10mM KCl, 1.5 mM KH2PO4, 8 mM Na2HPO4). Filter discs were 
soaked in 2 mL each of Optiphase Hi-Safe 3 (Wallac) for at least 6 hour, 2.5 mL Perkin Elmer 
Ultima Gold Scintillation cocktail was added and the total radioactivity was determined by a 
liquid-scintillation counting system (LS5000 CE; Beckman Coulter, Fullerton, CA). 
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4.1.5.3 [3H]-Dopamine Autoradiography 
After experiments were terminated, tissues were mounted onto silane-coated microscope 
slides and allowed to dry at room temperature. The slides were then placed in the chamber of the 
Beta-Imager 2000 instrument (BioSpace Lab, Cambridge, MA) and data were collected from the 
brain sections for 12 hours. The levels of bound radioactivity in striatum (cpm/mm2) were 
directly determined by counting the number of beta-particles emerging from the delineated area 
using the image analysis software, BetaVision (BioSpace  Lab, Cambridge, MA). 
4.1.5.4 Data Analysis 
Data from binding experiments were analyzed using nonlinear least-squares curve-fitting 
method (Prism 5.01, GraphPad Software Inc, San Diego, CA). Bound [3H]-DA was calculated 
using the method of Golds et al 
31
, to correct for radioligand depletion. Bound radioligand 
concentration was taken as total-bound minus free concentration in the absence of competitor. 
Data were fitted to four-parameter logistic equations, and the best fit between a variable Hill 
coefficient and a Hill coefficient fixed to unity was determined using an F-test. The statistical 
significance of differences between data was determined at the 0.05 level, using ANOVA or 
Student‘s t test, as appropriate.  At p<0.05, statistical significance was considered to be achieved. 
   
4.1.6  Ex vivo dopamine receptor binding  
4.1.6.1 Animal dosing  
Twenty-seven Sprague-Dawley rats weighing 280 to 320 g were used in these studies. 
Due to lack of brain penetration of dopamine, all test articles were injected directly into the 
cerebral parenchyma. Each group (n=4 rats per group) received 8 mg/kg intracerebral injections 
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of cold dopamine (with or without the selective dopamine inhibitor GBR12783), dopamine-
AuNPs (with or without GBR12783). AuNP solution mixed with dopamine, or mixed with brain 
matrix served as control. Increasing concentrations of dopamine (ranging from 0 – 1.3uM) were 
evaluated. Representative flow diagram of receptor occupancy protocol is shown in Figure 4-1-3. 
Rats were anesthetized 50 minutes after administration. Anesthesia was induced with 5% 
isoflurane in an induction box and maintained with 2% isoflurane administered in a 50:50 air-
oxygen mixture. A total of 120ug of atropine was administered intraperitoneally immediately 
after induction. Blood oxygen saturation and heart rate were monitored throughout the procedure 
(pulseoximeter; Nellcor), and temperature was maintained at 37°C using a locally manufactured 
rectal temperature–regulated heating pad and heating lamp. Rats were then decapitated and 
striatal tissues were excised, pooled, and stored at 70°C until used.  For each rat, one striatum 
was used for binding assays, and the contralateral striatum was used for autoradiography. The 
striatum side (left and right) used for the binding assays was counterbalanced from one rat to the 
other.  
4.1.6.2 Tissue preparation  
Briefly, the tissues were thawed and homogenized in a glass Teflon homogenizer at 500 
rpm in ice-cold 50 mM Tris-HCL buffer pH 7.4 for 20 minutes. The homogenates were 
centrifuged at 20,000 g for 20 mins at 5°C. The resultant pellets were rehomogenized in the same 
buffer and centrifuged again. The supernatant was discarded and the final pellets were 
resuspended in 5 to 10 mL assay buffer (50 mM Tris preset, 120 mM NaC1,5 mM KCI, 2 
mMCaCl2 and 1mM MgCl2). The protein concentration of homogenate was determined by the 
methods of Lowry and Bradford.
 32
  The samples were stored at approximately -80°C until used.  
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4.1.6.3 Competitive binding 
 The assays were performed as described previously.
33
  Briefly, striatal membranes (50ug 
protein per well) were incubated with [3H]-DA (56 - 62 mCi/mmol specific activity) in assay 
buffer (50 mM Tris preset, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, pH 7.4). 
Incubation was for 45 minutes at 37°C. All assays were performed in duplicates. The reaction 
was terminated by rapid filtration through GF/B filter mats presoaked in 0.3% 
polyethyleneimine, followed by three 1mL washes with ice-cold 50 mM Tris –HCl buffer (pH 
7.4). Filters and incubates were dissolved in 4 mL of scintillant (Ready Solve; Beckman Coulter) 
at room temperature. Radioactivity binding was determined by a liquid-scintillation counting 
system (LS5000 CE; Beckman Coulter, Fullerton, CA). 
 
4.1.6.4 Autoradiography 
 Slide-mounted sections were allowed to equilibrate to room temperature for 
approximately one hour and encircled using a PAP Pen (Dako Denmark A/S, Glostrup, 
Denmark). Assay solutions were removed by aspiration. Slides were dipped briefly in ice-cold 
distilled water to remove buffer salts and allowed to dry at room temperature. The slides were 
then placed in the chamber of the Beta-Imager 2000 instrument (BioSpace Lab, Cambridge, MA) 
and data were collected. The levels of bound radioactivity in striatum (cpm/mm2) were directly 
determined by counting the number of β-particles emerging from the delineated area using the 
image analysis software, BetaVision (BioSpace Lab, Cambridge, MA). 
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4.1.6.5 Data analysis 
 Nonlinear least-squares fitting of the data were performed using GraphPad Prism 5.01 
(GraphPad Inc, San Diego CA) data analysis software. Competition data was fitted to four-
parameter logistic equations, and the best fit between a variable Hill coefficient and a Hill 
coefficient fixed to unity was determined using an F-test. The ratio of counts per milligram of 
tissue in the striatum provided a measure of the total number of binding sites (specific and 
nonspecific) for [3H]-DA. The ratio of counts per milligram of tissue, after rat exposure to GBR 
1278, is used to define specific binding and correct data. Percent dopamine receptor occupancy 
(D2/D3-RO) in treated samples was calculated as (binding in treatment group – binding in 
vehicle group) /(binding in vehicle group). The percentage of [3H]-DA remaining in the presence 
of the test articles was plotted against the concentrations of dopamine or AuNPs. The statistical 
significance of differences between data was determined at the 0.05 level, using ANOVA or 
Student‘s t test, as appropriate.  When, p<0.05, statistical significance was considered to be 
achieved. 
4.1.7 In vivo dopamine receptor binding 
4.1.7.1 Animal dosing  
Twenty-four (n=4 per group) Sprague-Dawley rats weighing 280 to 320 grams were used 
in these studies. Due to lack of brain penetration of dopamine, and AuNPs with article size 
greater than 5 nm, all articles were injection directly into the cerebral parenchyma.  Each group 
received 8 mg/kg injection of 5, 15, 50, 100, 200 nm DA-AuNPs, and the dopamine inhibitor 
GBR12783. One group of rats received an intravenous injection of DA-AuNPs in order to 
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confirm BBB penetration.  A representative flow diagram of receptor occupancy protocol is 
shown in Figure 4-1-3. 
4.1.7.2 Competitive binding and Tissue preparation 
Fifteen minutes after receiving test articles, each rat received 8.0 μL of [3H]-DA (56–62 
mCi/mmol specific activity) intracerebrally. The concentration of the [3H]-DA solution was 0.9 
μCi/μL, equivalent to 3μg /μL. Rats were anesthetized, decapitated and the brains were removed 
immediately from the skull. The brain for autoradiographic imaging was placed into a brain mold 
with the region of interest uppermost. This was covered thoroughly with Tissue-Tek (Sakura 
Finetek Europe, Zoeterwoude, The Netherlands) and flash frozen in isopentane (cooled to 
between -20°C and -30°C with dry ice).  
Tissues were processed as previously published.
34
 Briefly, sagittal sections containing 
striata 1–1.7 mm from bregma, were cut with a VT1000S vibratome (Leica, Nussloch, 
Germany), thaw-mounted onto silane-coated microscope slides and stored in bubbled artificial 
CSF (ACSF) with kynurenic acid (1 uM) for 30 minutes. Six adjacent brain slices from the same 
animal were collected per microscope slide. Sections were encircled using a PAP Pen (Dako 
Denmark A/S, Glostrup, Denmark). All the sections were then washed twice for 2 minutes, each 
with 200 uL of ice-cold buffer (3 mm MgCl2, 1 mm KH2PO4, pH 6.8). Slides were then dipped 
briefly in ice-cold distilled water to remove buffer salts and allowed to dry at room temperature.  
 
4.1.7.3 Autoradiographic imaging 
The slides were then placed in the chamber of the Beta-Imager 2000 instrument 
(BioSpace Lab, Cambridge, MA), and data were collected from the brain sections for 12 hours. 
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The levels of bound radioactivity in striatum (cpm/mm
2
) were directly determined by counting 
the number of beta-particles emerging from the delineated area using the image analysis 
software, BetaVision (BioSpace Lab, Cambridge, MA). The ratio of counts per milligram of 
tissue in the striatum provided a measure of the total number of binding sites (specific and 
nonspecific) for [3H]-DA. The ratio of counts per milligram of tissue after rat exposure to 
GBR1278, is used to define specific binding and correct the data. Percent dopamine receptor 
occupancy (D2-RO) in treated samples was calculated.  
4.1.7.4 TEM imaging of rat brain striata  
Striata specimens of the rats injected intravenously with 5nm DA-AuNPs were fixed in 
chilled glutaraldehyde and then embedded in sample block. 60-80 nm thin sections are cut on 
ultramicrotome using a diamond knife. Sections are then air-dried for several hours overnight in 
a protective environment and placed onto carbon-coated formvar-covered support grids. The 
specimen was examined under a transmission electron microscope (FEI Tecnai, G2 Sphera) at 
10,000 – 200,000 times magnification using accelerating voltages between 50kV and 120kV.  
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Figure 4-1-3. Flow diagram of ex vivo and in vivo receptor occupancy protocol. Diagram 
shows the differences between ex vivo and in vivo procedure.  
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4.2 RESULTS AND DISCUSSION 
 
4.2.1 DA-AuNP synthesis and characterization  
 
We developed a robust process (figures 2) to prepare DA-AuNPs with particle sizes from 
5 to 200 nm (Figure 4-2-1). Efficient mixing and repeated recirculation of NP and drug solutions 
ensured maximum loading of dopamine unto AuNPs. The reaction was terminated after 2.5 
hours when free drug concentration determined by HPLC achieved steady-state (Figure 4-1-2).  
A gradual change in the color of the effluent solution from intense red to a consistent dark purple 
after 4 hours of operation, provided visual confirmation of HPLC results.  
During the chemical synthesis of gold NPs by citrate reduction of auric acid, NP size and 
stability were controlled by the negatively charged citrate ions at the freshly formed NP surface. 
The charge helps quench NP growth and accounts for the negative zeta potential of AuNPs.
35
 
Generally NPs with zeta potential above ±30mV prevents aggregation of the particles and result 
in stable suspensions.
36
 In our experiment, the size of the NPs decreased from 200 to 15 nm as 
the ratio of citrate to chloroauric acid increased. Correspondingly, the zeta potential increased 
from -29 to -36 mV suggesting that citrate molecules actively bind to the Au surface. 
Subsequent addition of dopamine to the citrate stabilized NPs changed the zeta potential 
from negative to positive (+7.9 to +9.6). This change of surface charge occurs due to 
displacement of citrate ions and association of dopamine ligands to the gold surface. Strong 
interaction between Au(3+) and the lone electron pair on the nitrogen atom of the amine group, 
is likely responsible for long term stabilization of dopamine NPs.
37, 38
 Table 4-1 summarizes the 
properties of AuNPs. 
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Figure 4-2-1. Particle size histogram(Left) and Transmission electront micrograph(Right) 
of DA-AuNPs 5 nm (A), 15nm (B),  50nm (C), 100nm (D), 200nm (E).   
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 Figure 4-2-2. Reaction solution dopamine concentration-time curve. Free dopamine  
          in solution decreases as dopamine is bound to the surface of AuNPs. 
 
 
Table 4-1. Characterization of 5, 15, 50, 100 and 200nm DA-AuNPs. 
 
 
Particle size (nm) 
 
5 ± 1.30 15 ± 2.30 50 ± 5.65 100 ± 5.56 200 ± 7.56 
Sodium citrate (mM) 
 
1.51 15.4
 
 1.74 1.41 1.15 
Polydispersity Index     
 
0.27 ± 0.05 0.24 ± 0.05 0.19 ± 0.08 0.31 ± 0.07 0.20 ± 0.06 
Zeta potential (mV) 
(Citrate-AuNP) 
-29.3 ± 0.91 
 
-32.1 ± 1.07 
 
-33.2 ± 0.71 
 
 -35.3 ± 1.01 
 
  -36.4 ± 1.21 
 
Zeta potential (mV) 
(Dopamine-AuNP) 
+7.9 ± 0.91 
 
+8.3 ± 1.07 
 
+8.8 ± 0.71 
 
  +9.4 ± 1.01 
 
   +9.6 ± 1.21 
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4.2.2 Human whole-cell dopamine receptor binding  
 
Chinese hamster ovary (CHO) cell lines expressing the short isoform of the human D2 
dopamine receptor (CHO-D2S) cells were used for competition binding experiments. The 
binding curves are presented in Figure 4-2-3, and showed dose-dependent binding of DA-AuNPs 
to D2 receptors. The radioligand (3H-DA) was displaced from receptors in the presence of a cold 
DA-AuNP challenge. The affinity of DA-AuNPs for human D2 receptor (D2R) was found to be 
10-fold greater than free dopamine. 3H-DA binding decreased dramatically as the concentration 
of dopamine increased confirming that DA-AuNPs have greater affinity for D2R than dopamine 
alone. Furthermore, in the presence of dopamine inhibitor (GBR 12783) the binding of DA-
AuNPs decreased to levels similar to those observed with free dopamine incubated with 
GBR12783. This provides direct evidence that the dopamine receptor is responsible for the 
binding with DA-AuNPs. GBR 12783 1-[2-(diphenylmethoxy) ethyl] 4-(3-phenyl-2-propenyl)-
piperazine, is the most potent and specific DA uptake inhibitor ever described.
39
 
Unconjugated gold nanoparticles failed to compete for dopamine binding sites, and 
essentially no receptor binding was observed with AuNPs alone. The mixture of dopamine and 
AuNPs exhibited at least 3 to 5-fold less binding than dopamine alone, and fifty percent less than 
DA-AuNPs. As expected, the affinity of dopamine increased with the concentration of dopamine 
in the mixture. When GBR12783 was added to the mixture, previous AuNP binding was 
reestablished.  These findings suggest that the binding of dopamine and AuNP mixture was 
essentially due to dopamine, not AuNPs. We further infer from these results that the increase in 
dopamine receptor binding (as observed with DA-AuNPs) is strongest in the bound form of 
dopamine compared to the unconjugated form. These results also confirm that drugs conjugated 
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to AuNPs do not lose their biological activity, but rather may experience an enhancement in their 
potency.  
Autoradiographic images of brain sections confirm these findings as well. In the presence 
of GBR 12783, binding of AuNPs (or mixture of dopamine and AuNPs) to DA receptors is 
turned off as shown by loss of radioactivity. DA-AuNPs also displaced dopamine radioligand, 
however as expected, the receptors retained some amount of DA binding in the presence of GBR 
12783. 
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Figure 4-2-3. (A) Binding curves illustrating CHO-human D2 receptor binding with increasing 
dose of test agents.  (B) Autoradiographic images showing [
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4.2.3 Ex vivo dopamine receptor binding 
 
Ex vivo binding and autoradiography studies of dopamine-AuNPs were conducted in 
striatal membrane homogenate from Sprague-Dawley rats. The baseline binding of radioligand to 
D2R and the changes in radioligand binding due to DA-AuNP challenge were determined. The 
DA-AuNPs show significantly (p<0.05) high affinity to central D2R, in a dose-dependent 
manner (Figure 4-2-4A). There is gradual and complete inhibition of [3H]-DA binding with 
increasing doses of DA-AuNPs. In comparison, AuNPs and other combinations tested could only 
partially prevent [3H]-DA binding at the highest dose concentration. A correlation therefore 
exists between this ability to bind D2 receptors and dose.  Of all agents tested, DA-AuNPs 
produced the highest receptor occupancy, approaching 100% at 1uM dose. Free dopamine 
achieves only 80% occupancy at 1uM.  
The experiments were also performed in the presence of the DA uptake blocker 1 μM 
GBR 12783
40
 added to the medium 2 hours before sample collection. The receptor occupancy of 
DA-AuNP and free DA decreased in the presence of GBR 12783. However, in the presence of 
GBR12783, the affinity of DA-AuNP was slightly lower compared to dopamine. Loss of binding 
in the presence of inhibitors confirms the involvement of dopamine receptors in the binding with 
DA-AuNPs, and excludes off target binding. 
Unconjugated NPs or a mixture of dopamine and AuNPs showed marginal binding. Once 
again, we can infer that bound dopamine rather than free dopamine was responsible for the 
increase in the affinity to D2 receptor relative to free DA. The results are consistent with findings 
from binding studies using human dopamine receptor whole cells, and further confirmed by 
autoradiographic images of brain sections. [3H]-DA were bound to receptors and then displaced 
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by the more potent DA-AuNPs. Digital images, obtained with β-imager, showed complete 
inhibition of [3H]-DA at high doses of DA-AuNPs (Figure 4-2-4B). In comparison, a mixture of 
dopamine and AuNPs could only partially prevent [3H]-DA binding. [3H]-DA binding 
represents 100% D2 receptor occupancy, and was displaced from the DA receptor in the 
presence of GBR12783.  
The advantage of labeling the receptor on tissue sections (ex vivo) rather than in tissue 
homogenates (in vivo) has been already demonstrated.
41,42
 In that manner, the dissociation of the 
drug-receptor complex formed in vivo can be kept minimal by immediate freezing of the brains, 
omitting preincubations of the sections, and by using short incubations with the radioligand. The 
short incubation time is critical for ex vivo autoradiographic protocols, particularly when the 
method is used for evaluation of compounds with unknown properties.  
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Figure 4-2-4. (A) Mean binding curves illustrating the dose-dependent occupancy of D2 receptors by DA-
AuNPs and derivatives in rat brain striata. (B) [3H] Dopamine autoradiographic binding in rat brain striata 
after treatment with increasing doses of DA-AuNPs and derivatives. Digital images obtained after 
acquisition with the β-imager.  
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4.2.4 In vivo dopamine receptor binding 
 
Using dopamine (a poor brain penetrant) as the model drug, we investigated the effect of 
NP size on the binding affinity of dopamine. NPs with sizes 5, 15, 50, 100, and 200 nm were 
injected directly into cerebral parenchyma of Sprague-Dawley rats following pretreatment with 
radioligand. From the dopamine receptor occupancy curves (Figure 4-2-5A), we see that D2-RO 
increased with decreasing particle size of 5nm DA-AuNPs. The RO of 5, 15, 50nm AuNPs were 
90%, 60%, and 20%, respectively. The 100 and 200 nm NPs each registered meager occupancies 
of about 5%. 5nm DA-AuNP, administered either intracranial or intravenously, provided 5 % 
and 10% more binding affinity, respectively than dopamine alone. 
Small NPs, because of their large surface area may provide multiple sites for binding 
with receptors as well as promote stronger and more thermodynamically stable bonds. 
Furthermore, the spatial distribution of receptor binding and radioactivity in rat brain sections 
(Figure 4-2-5B) were confirmed in radiographic images. As expected, the dopamine inhibitor -
GBR 12783, displaced dopamine from the dopamine receptor and this is reflected in the loss of 
radioactivity (Figure 4-2-5B).   
Since receptor occupancy measurement is a good predictor of the drug free fraction 
available within brain interstitial space, the pharmacodynamics and efficacy after injection of 
DA-AuNPs can be inferred. It is expected that the AuNPs will enhance the dopaminergic effects 
of dopamine and potentially other CNS agents, as a result of higher brain penetration and binding 
conferred on drug molecules by AuNPs. However, it is unclear if DA retains the agonist binding, 
or switches from agonistic to antagonistic after conjugation to AuNPs. Functional assays may be 
needed to probe the mode of interaction between DA-AuNP and DA receptor. More studies are 
also needed to determine the selectivity of DA-AuNP for dopamine receptors.  
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5nm drug-NPs may provide a simple, inexpensive and safer alternative to radioligands 
for evaluating the potency of CNS drug candidate. Together these studies also show that the 
conjugation of dopamine to AuNPs does not diminish dopamine binding affinity. Rather, affinity 
and consequently pharmacological activity increased. To date, no studies have demonstrated the 
ability of dopamine conjugated NP to cross the BBB. This is also the first time that receptor 
binding studies involving NPs have been undertaken.  
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Figure 4-2-5 (A)DA receptor binding of 5-200nm DA-AuNPs in rat brain striata (B)Autoradiographic 
images of rat brain sagittal sections showing spatial distribution of different sizes of DA-AuNP.  
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4.2.5 TEM imaging of rat brain striata  
 
The BBB penetration and distribution of DA-AuNPs in rat brain were investigated at the 
subcellular level using transmission electron microscopy (TEM). TEM imaging on ultra-thin 
sections of rat brain was used to confirm BBB penetration of DA-AuNPs after intravenous 
injection. The resulting TEM images showed NPs in brain parenchyma. Specifically DA-AuNPs 
were found inside the cytoplasm of vascular endothelial cells as well as inside neurons, which 
are not attached to cerebral vessels (Figure 4-2-6). The presence of DA-AuNPs inside neurons 
indicates that the nanoparticles diffused through the vascular endothelial cells at the BBB before 
reaching the cerebral parenchyma. The results provide direct evidence that in addition to 
effective D2R binding, DA-AuNPs penetrated the BBB and spread into the brain parenchyma. 
Similarly we previously demonstrated that 6-MPR-AuNPs unlike free 6-MPR could cross the 
BBB.
43
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Figure 4-2-6. Electron microscopy (TEM) images of rat brain section showing gold 
nanoparticles inside brain parenchyma after intravenous  injection with 5nm dopamine-AuNPs. 
AuNPs (red arrows) are shown inside the cerebral vascular lumen(LU), cytoplasm of 
endothelial cells (EC)and neuronal tissues. Also shown are lumen (LU), endothelial cell (EC), 
neuron (NEU), tight junction (TJ), basal lamina(BL), and astrocytic end-feet (AS). A and B are 
different views of EM slides. 
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4.3 CONCLUSIONS 
 
 
This study was designed to answer the central question of whether conjugation of 
dopamine to AuNPs might enhance its brain penetration and dopamine-binding affinity to D2R. 
To this end, we are the first to describe the use of novel dopamine-conjugated AuNPs to 
overcome the low BBB permeability of dopamine, while enhancing dopaminergic receptor 
binding (and therefore pharmacological activity). The study shows that AuNPs enabled BBB 
penetration of dopamine, while maintaining dopamine efficacy.  Furthermore, the AuNPs 
increased the binding affinity of dopamine to doparminergic receptors in the brain. 
 In addition to potentially enabling unique therapies for dopamine, AuNPs may also offer 
a safer, more potent and inexpensive alternative to radioligands for preclinical and clinical 
receptor binding studies. This research also provides a drug-delivery tool for testing potential 
CNS drug candidates that otherwise cannot be evaluated due to lack of BBB permeability. 
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CHAPTER 5 
THESIS CONCLUSION 
5.0 FUTURE RESEARCH AND PERSPECTIVES  
5.1.1 Central nervous system nanonotherapeutics 
 
Application of nanotechnology to neuroscience is already having significant effects, 
which will only continue for the foreseeable future. In the coming years, nanoparticles will 
provide simultaneous brain imaging, diagnostics and therapy (so-called theranostic). Similarly, 
intelligent molecular ―trojan horse‖ will someday be able to effectively ferry drugs and non-viral 
plasmid DNA into the brain. Nanoparticles can facilitate this by binding to an exofacial epitope 
that is spatially removed from the binding site of the endogenous ligand on the BBB receptor. 
This will allow drug nanoparticles to ―piggy back‖ across the BBB via receptor-mediated 
transytosis without interfering with endogenous transport systems. In the next decade it is 
expected that new multifunctional therapeutics consisting of a homing device for targeting, 
imaging moiety for sensing/imaging, and drug therapy will translate into clinical use.  
Future brain targeting studies involving nanoparticles will need to determine the extent, 
rate, and effect of drug and nanoparticle uptake into the brain. Parameters like administration 
route, sampling time points, and the way in which the data are presented should be taken into 
account. Furthermore, the intracellular fate of nanoparticles, remains unclear. There is limited 
information on the effect of the physicochemical properties of nanoparticles on their distribution, 
cellular uptake, metabolism, accumulation and elimination. Also, though several mechanisms 
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including receptor mediated endocytosis have been proposed to explain nanoparticle transport 
across the BBB, more investigations are still needed to fully elucidate the binding, brain uptake 
and transport mechanism of gold nanoparticles.  Finally, faster and more sensitive detection 
methods are needed to study uptake and trafficking of nanoparticles in biological systems. 
Current static imaging techniques for studying the biodistribution of nanoparticles cannot detect 
small fractions of nanoparticles in vascular beds, blood stream, and inner organs of the body.  
5.1.2. Nanotoxicity  
 
One significant benefit of nanoparticles as a drug carrier is the prolonged mean residence 
time in the body. While this may desirably increase the exposure of drugs to disease targets, it 
can also increase toxicity. This is especially true for nanoparticles because of their large surface 
area, and therefore unique physicochemical and biological properties.
 1,2
  Nanoparticles may also 
have the potential for generating free radicals and exhibit oxidative tendency depending on their 
surface characteristics. There are only a few long term toxicology studies on nanomaterials, 
primarily SiO2, CNT, and TiO2. The available information indicates that certain nanoparticles 
may be genotoxic or phototoxic. However, the toxicokinetics and metabolism of nanomaterials 
have not been studied in detail. In particular, there is limited information about how the 
physicochemical parameters of nanoparticles affect absorption and transport across barriers of 
skin, gut, lungs and eyes. Additionally, the accumulation, metabolism and excretion from 
secondary target organs require further research.  
Current studies with 6MPR-conjugated AuNPs or dopamine-conjugated AuNPs were 
well-tolerated with no adverse events observed. However, there is still a need for data-extensive 
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toxicological evaluation of AuNPs and other metal nanoparticles with respect to their systemic 
and CNS effects.  These questions are well outside the scope of this thesis.  
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5.2 CONCLUDING REMARKS  
 
 
The vast majority of small molecule drugs (>98%) do not cross the BBB, and therefore 
cannot treat CNS diseases. As discussed in chapter one, several strategies to get drugs across the 
BBB have been attempted, with limited success. These involve direct injection of drugs into the 
brain, transport via the olfactory and trigeminal nerves innervating the nasal passages, or opening 
of BBB tight-junctions by means of osmotic agents, as well as exploiting  endogenous transport 
systems within the BBB using medicinal chemistry strategies.  
Several studies are available on the utility of AuNPs for diagnostic and therapeutic 
applications. However, there are no reported cases of using AuNPs to enhance the brain 
penetration and pharmacological activity of CNS drugs. Therefore, in this thesis, we describe the 
successful use of a novel CNS drug delivery system involving conjugating drugs to 5nm AuNPs. 
We combined detailed in vitro and in vivo experiments with imaging and bioanalytical 
techniques to investigate the pharmacokinetics, BBB penetration, and receptor binding of drugs 
conjugated to AuNPs. Specifically, we demonstrated that 6-MPR and dopamine conjugated to 
AuNP are able to cross the BBB into brain parenchyma.  
Our findings also show that AuNPs significantly inhibit xanthine oxidase metabolism of 
6-MPR. Finally, based on receptor binding experiments with dopamine-AuNPs, it is observed 
that the AuNPs not only enabled brain penetration of dopamine, but they also increased the 
binding affinity of dopamine to dopaminergic receptors in the brain. To our knowledge, this is 
the first time transvascular delivery of a therapeutic agent across the BBB (with the possibility of 
also enhancing drug receptor-binding potential) has been achieved using small AuNPs.  
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Even though the present study primarily focused on the brain uptake of model 
compounds (6-MPR and dopamine), the strategy described here is applicable to a wide range of 
drug candidates with low BBB permeability. Future advances in CNS biology, neuroimaging and 
bioanalytical techniques, specifically as they pertain to nanoscale systems, will provide further 
insights into the design, performance and toxicity of drug delivery systems involving 
nanomaterials.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  133  
 
 
 
REFERENCES 
 
 
1   Soenena, S.J.; Rivera-Gilb, P.; Montenegrob, J-M.; Parakb, W.J.; De Smedta, S.D. Cellular toxicity of 
inorganic nanoparticles: Common aspects and guidelines for improved nanotoxicity evaluation,  Nano 
Today. 2011, 6 (5), 446–465. 
2   Karakoti, A.S.; Hench, L.; Seal, S. The potential toxicity of nanomaterials – the role of surfaces. J 
Miner, Met Mater Soc. 2006, 58, 77–82. 
 
